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A diverse T cell receptor (TCR) repertoire is essential for the adaptive 
immune system. T cells have to recognise and react to a huge variety of 
potential pathogens and at the same time maintain tolerance to self-antigens. 
TCR repertoire is established in the thymus during T cell development. 
Previous estimates of TCR diversity have studied the mature repertoire 
in the peripheral blood, identifying 1-3 x 106 unique TCRβ and 0.5 x 
106 TCRα sequences, but the human intrathymic diversity has not been 
previously measured. In this thesis I provide the fi rst estimate of the total 
TCR diversity in the human thymus. We have used high-throughput TCR 
sequencing and detected up to 10.3 x 106 unique TCRβ sequences and 3.7 
x 106 TCRα sequences, which sets a new lower limit for TCR diversity. 
Computational estimators preseq, DivE and Chao2 produced 40 to 70 x 106 
unique TCRβ sequences and 60 to 100 x 106 TCRα sequences in the human 
thymus. 
Somatic recombination produces a diverse thymic TCR repertoire that 
includes also the thymocytes instructed to develop into natural regulatory T 
cells. They are characterised by stable expression of the forkhead/winged-
helix transcription factor FOXP3 and demethylation of Treg-specifi c-
demethylated region (TSDR). Regulatory T cells develop as a separate cell 
lineage in the thymus and commitment occurs already at the CD4+CD8+ 
double positive (DP) stage. TCR-mediated signalling instructs the selection 
to the regulatory lineage and cytokines promote Treg development. We 
have used high-throughput TCR sequencing and methylation analysis of 
TSDR to track the timing of Treg commitment. Comparing the common 
TCR sequences showed that regulatory DP CD25+ and CD4SP CD25+ 
populations were clearly closer to each other than any other population, 
indicating that they are part of the common clonal and developmental 
pathway. The methylation analysis of TSDR in the DP and CD4+ single 
positive (SP) regulatory populations showed no diff erence between them. 
Thus a stable Treg phenotype can already be detected at the double positive 
stage.
In this thesis I have studied the role of common γ chain cytokines in regulatory 
T cell development in the human thymus. Since thymic commitment of 
human Tregs begins at the double positive stage I have studied the eff ects 
and mechanisms of interleukin-2, interleukin-7 and interleukin-15 at the 
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DP phase. Previous studies in murine models have established a two-step 
model. According to these studies, TCR signalling upregulates interleukin-2 
receptor (IL-2R) and increases the responsiveness of developing Tregs to 
common γ chain cytokines that induce the expression of FOXP3. IL-7 has 
been considered to have a minor role in Treg development since mature 
peripheral Tregs express low levels of interleukin-7 receptor (IL-7R). We 
show that during thymic development DP FOXP3+ thymocytes upregulate 
IL-7R and are responsive to IL-7. At the DP stage TCR-signalling dictates 
Treg maturation during positive selection and IL-15 enhances Treg survival. 
After positive selection IL-2 and IL-7 increase the expression of  FOXP3 
and anti-apoptotic protein BCL-2 (B cell lymphoma 2) and promote Treg 
phenotype. DP FOXP3+ cells are highly susceptible to apoptosis but all 
three cytokines enhance their survival. Suppressing apoptosis is a key 
mechanism in promoting Treg development at the DP and CD4SP stage in 
the human thymus. 
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TIIVISTELMÄ
Laaja ja monimuotoinen T-solureseptorien repertuaari on välttämätön osa 
adaptiivista immuunipuolustusta. T-solujen täytyy tunnistaa valtava kirjo 
erilaisia vieraita patogeeneja, mutta samaan aikaan ylläpitää toleranssia ja 
jättää omat kudokset rauhaan. T-solujen repertuaari syntyy kateenkorvassa. 
Aiemmat arviot T-solureseptorien monimuotoisuudesta perustuvat 
kypsiin T-soluihin ihmisen verenkierrossa. Näissä on tunnistettu 1-3 x 
106 uniikkia T-solureseptorin beeta-ketjun sekvenssiä ja 0.5 x 106 alfa-
ketjun sekvenssiä. Ihmisen kateenkorvan T-solujen repertuaarin laajuutta 
ei ole aiemmin tutkittu. Tässä väitöskirjatyössä on ensimmäisen kerran 
mitattu ja arvioitu ihmisen kateenkorvan T-solureseptorien diversiteettia. 
Sekvensoimme 10.3 x 106 uniikkia T-solureseptorin beeta-ketjua ja 3.7 x 106 
alfa-ketjua. Nämä tulokset asettavat uuden alarajan reseptorien laajuudelle 
ja monimuotoisuudelle ihmisessä. Käytimme lisäksi matemaattisia 
estimaattoreita preseq, DivE ja Chao2, jotka arvioivat koko kateenkorvan 
diversiteetiksi 40-70 x 106 uniikkia beeta-ketjua ja 60-100 x 106 uniikkia 
alfa-ketjua. 
Kateenkorvan somaattisen rekombinaation koneisto tuottaa laajan 
T-solureseptorirepertuaarin, joka sisältää myös luonnollisiksi säätelijä-T-
soluiksi kehittyvät tymosyytit. Luonnolliset säätelijä-T-solut ilmentävät 
transkriptiotekijä FOXP3:a ja niiden geeneissä TSDR-alue on pysyvästi 
demetyloitunut eli siitä puuttuvat geenin hiljentävät epigeneettiset 
merkit. Säätelijä-T-solut kehittyvät omana solulinjanaan kateenkorvassa 
ja valikoituvat kehitykseen jo CD4+CD8+ tuplapositiivisessa vaiheessa. 
T-solureseptorin kautta välittyvät signaalit ohjaavat solujen valikoitumista 
säätelijä-linjalle ja sytokiinit edistävät myös säätelijäsolujen kehitystä. Tässä 
työssä olemme käyttäneet T-solureseptorien repertuaarin sekvensointia 
sekä TSDR-alueen metylaatioanalyysia selvittääksemme säätelijä-T-
solulinjalle valikoitumisen ajoitusta. Vertailimme kateenkorvassa CD25+ 
populaatioiden T-solurepertuaaria CD4+CD8+ tuplapositiivisessa sekä 
CD4-positiivisessa kehitysvaiheessa. Yhteisiä sekvenssejä vertaamalla 
totesimme, että nämä molemmat CD25+ ryhmät olivat repertuaariltaan 
selvästi lähimpinä toisiaan. Tämä osoittaa niiden olevan osa samaa 
säätelijä-T-solujen kehityskaarta. Populaatioissa ei ollut myöskään mitään 
eroa metylaatiostatuksessa. Vakaa säätelijä-T-solun fenotyyppi voidaan 
havaita jo tuplapositiivisessa kehitysvaiheessa. 
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Olen tässä väitöskirjatyössä tutkinut sytokiinien roolia säätelijä-T-
solujen kehityksessä ihmisen kateenkorvassa. Nämä solut valikoituvat 
kehityslinjalleen jo tuplapositiivisessa vaiheessa, joten olen keskittynyt 
interleukiini-2:n, interleukiini-7:n ja interleukiini-15:n vaikutuksiin ja 
mekanismeihin tässä kehitysvaiheessa. Aiemmat tutkimukset hiirimalleissa 
ovat luoneet perustan kahden-askeleen-mallille: T-solureseptorin kautta 
välittyvä signalointi lisää CD25-molekyylin määrää solujen pinnalla ja 
näin herkistää niitä sytokiinien vaikutukselle. Sytokiinit käynnistävät 
FOXP3:n ilmentymisen. Interleukiini-7:lla on aiemmin oletettu olevan 
vain pieni rooli säätelijä-T-solujen kehityksessä, sillä verenkierron 
kypsät solut eivät ilmennä sen reseptoria pinnallaan. Tässä tutkimuksessa 
osoitamme, että kehityksen aikana tuplapositiivisessa vaiheessa FOXP3+ 
tymosyyteissa reseptorin ilmentyminen solujen pinnalla lisääntyy ja näin 
solut pystyvät reagoimaan sytokiinin IL-7 signalointiin. Tuplapositiivisessa 
kehitysvaiheessa T-solureseptorin kautta välittyvät signaalit ohjaavat 
säätelijä-T-solujen valikoitumista positiivisessa selektiossa, ja IL-15 
edistää solujen selviytymistä. Positiivisen selektion jälkeen IL-2 ja IL-7 
lisäävät FOXP3:n ja anti-apoptoottisen BCL-2:n ilmentymistä sekä 
edistävät säätelijäsolun fenotyyppiä. Tuplapositiiviset FOXP3-solut ovat 
hyvin alttiita solukuolemalle, mutta kaikki kolme sytokiinia edistävät 
niiden selviytymistä. Ohjelmoidun solukuoleman ehkäiseminen onkin 




AIRE autoimmune regulator gene/protein (human)
AP-1 activator protein 1
APC antigen presenting cell
APECED  autoimmune polyendocrinopathy-candidiasis-  
 ectodermal dystrophy
BCL B cell lymphoma
CCL chemokine (C-C motif) ligand
CCR7 C-C chemokine receptor 7
CD  cluster of diff erentiation
CDR complementarity determining region
CMJ corticomedullary junction
CNS conserved non-coding sequence
CXCR5 C-X-C chemokine receptor type 5
cTEC cortical thymic epithelial cell
CTLA-4 cytotoxic T-lymphocyte-associated protein 4
DC  dendritic cell
DGE digital expression matrices
DN double-negative, CD4- CD8-
DP double-positive CD4+ CD8+
ETP early thymic progenitor
FOXP3 forkhead box P3, gene/protein (human)
Foxp3 forkhead box P3, gene/protein (mouse)
GITR glucocorticoid-induced tumor necrosis factor receptor
GFP green fl uorescent protein
HLA human leukocyte antigen
HSC hematopoietic stem cell
ICOS inducible T-cell costimulatory





IPEX immune dysregulation, polyendocrinopathy,   
 enteropathy, X-linked
ISP immature single positive
ITAM immunoreceptor tyrosine-based activation motif
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iTreg induced regulatory T cell
JAK Janus tyrosine kinase
LAG-3 lymphocyte activation gene 3 protein
Lck lymphocyte-specifi c protein tyrosine kinase
mDC myeloid dendritic cell
MHC major histocompatibility complex
MFI  mean fl uorescence intensity
mRNA messenger ribonucleic acid
mTEC medullary thymic epithelial cell
mTOR mechanistic target of rapamycin
N-nucleotide nontemplated nucleotide
NF-kB nuclear factor kappa-light-chain-enhancer of activated B  
 cells
NFAT nuclear factor of activated T cells
NGS next generation sequencing
NKT natural killer T cell
Nrp neuropilin
nTreg natural regulatory T cell
P-nucleotide palindromic nucleotide
pDC plasmacytoid dendritic cell
PD-1 programmed death 1 receptor
PI3K phosphatidylinositol 3-kinase
pMHC complex of peptide and MHC
RAG1  recombination activating gene 1
RTE  recent thymic emigrant
S1P1 sphingosine 1-phosphate receptor 1
SOCS1 suppressor of cytokine signalling 1
SP single-positive
STAT signal-transducing activator of transcription
SCID-X1 severe combined immunodefi ciency X-linked
Tconv conventional T cell
TCR T cell receptor
T-bet T-box transcription factor
TdT terminal deoxynucleotidyl transferase
Tet ten-eleven-translocation
TGF-β transforming growth factor β
Tfh T follicular helper T cell
Th T helper cell
TNC thymic nurse cell
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TREC TCR excision circles
Treg  regulatory T cell
TRA tissue-restricted antigen
TSA tissue-specifi c antigen
TSDR Treg-cell specifi c demethylated region
TSLP thymic stromal lymphopoietin
TSP thymus seeding progenitor
UMI unique molecular identifi er
VDJ variable-diversity-joining
ZAP-70 zeta-chain associated protein kinase 70
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The human T cell repertoire is established in the thymus. It has to both 
defend the body against potential pathogens and maintain tolerance to self-
antigens. The genetic recombination machinery has to generate a diverse 
peripheral T cell population that acts effi  ciently as an essential part of 
the adaptive immune response but does not lead to harmful autoimmune 
reactions. The education of thymocytes includes positive and negative 
selection in the thymus. Positive selection ensures that developing 
thymocytes are functional and negative selection eliminates autoreactive 
T cells. 
Huge T cell receptor diversity is generated by somatic VDJ recombination. 
The specifi city of a TCR is primarily determined by a hypervariable area 
called the third complementarity-determining region (CDR3) in the α and β 
chains. In the VDJ recombination the non-contiguous Vβ, Dβ and Jβ gene 
segments are rearranged in the β chain locus and Vα and Jα gene segments in 
the α chain locus. Theoretically possible TCRβ diversity has been calculated 
to be 5x1011 but the actual diversity of an individual remains unknown 
since it cannot be directly measured. Previous estimates of peripheral TCR 
diversity have been based on sequencing T cell compartments in blood 
samples.
Regulatory T cells are a suppressive T cell population responsible for 
peripheral tolerance. They were fi rst identifi ed in 1995 as a CD25 expressing 
population with suppressive capabilities. In 2001 they were reported to 
be characterised by the transcription factor FOXP3 that regulates Treg 
development and function in the periphery. Tregs can diff erentiate from 
peripheral conventional T cells but the majority of the regulatory population 
are natural Tregs that derive from the thymus. Their developmental pathway 
has been extensively studied in murine models whereas in humans further 
research is needed. Tregs develop as a separate cell lineage in the thymus. 
TCR-mediated signalling instructs the selection to the Treg lineage and 
cytokines and other cofactors have been recognised as being essential for 
Treg maturation. 
In this thesis I have studied TCR diversity, regulatory T cell repertoire 
and Treg development in the human thymus. The primary TCR repertoire 
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generated in the thymus has not been previously measured although estimates 
of the peripheral diversity have been reported. Intrathymic TCR diversity 
gives insight into the mechanisms that generate a diverse functional TCR 
repertoire that can recognise the universe of pathogens and respond to the 
threat of them. Regulatory T cells are an indispensable part of tolerance in 
the human immune system. I have studied the timing of their commitment 
and the cytokines instructing their development in human thymic samples. 
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REVIEW OF THE LITERATURE
1. T CELL RECEPTOR
1.1 T lymphocytes
T cells are an essential part of the adaptive immune system and their 
development takes place in the thymus. B lymphocytes derive from the 
bone marrow and they are important eff ectors as part of humoral immunity. 
T cells are distinguished by the expression of a T cell receptor that in most 
cells consists of α and β chains. A 5% minority of T cells are γδ T cells. 
TCR is an αβ heterodimer that recognises peptide antigens presented in the 
major histocompatibility complex molecules (MHC). 
Peripheral naive T cells are activated by antigen-presenting cells (APCs) 
when TCR recognises the target peptide presented on the MHC. The 
co-receptor expression of the TCR divides T cells into CD4 and CD8 
populations. CD4 helper T cells provide activation signals to other cells 
and cytotoxic CD8 T cells kill cells infected by viruses. CD4 helper T cells 
recognise antigen peptides bound to MHC II molecules and cytotoxic CD8 
T cells peptides bound to MHC I molecules. Regulatory T cells prevent 
autoimmunity reactions by suppressing other lymphocytes. 
1.1.1 CD4 lymphocytes
CD4 T helper cells (Th cells) are an essential part of the adaptive immune 
system and form the majority of peripheral T cells. They activate other 
immune cells by providing cytokines, regulating immune responses, 
promoting B cell maturation and antibody secretion, enhancing CD8 T cell 
function and supporting macrophages. They express CD40L that binds to 
CD40 expressed by antigen-presenting dendritic cells, B cells, monocytes 
and macrophages. CD4 helper T cells recognise antigen peptides bound 
to MHC II molecules on the antigen presenting cells (APCs) leading to 
T cell activation in the lymph nodes. The second signal is provided by 
the interaction of co-stimulatory molecules CD28 and CD80/CD86 
between the helper T cell and APC. This is required to prevent harmful 
autoimmune reactions. Following activation Th cells proliferate and secrete 
cytokines, particularly IL-2. The cytokine environment instructs Th cells to 
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diff erentiate into multiple T cell subpopulations. IL-12 stimulation drives 
Th1 and IL-4 Th2 maturation. Together IL-4 and transforming growth 
factor β (TGF-β) drive the diff erentiation of Th9 and IL-6 while TGF-β 
drives the diff erentiation of Th17 cells (Raphael, Nalawade et al. 2015). 
Th1 cells regulate immune responses against viruses and intracellular 
pathogens. IL-12 is the main triggering cytokine of Th1 cells that activate 
macrophages, CD8 T cells and B cells. Th1 cells drive macrophages to 
destroy intracellular bacteria by secreting IFN- γ and promoting the 
proliferation of CD8 cytotoxic T cells. 
Th2 immune response is required against extracellular parasites. Th2 cells 
activate eosinophils, basophils, mast cells and B cells and produce IL-4, IL-5 
and IL-13. Th2 response is triggered by IL-4 and plays a role in preventing 
the harmful allergy reactions. Th17 cells are a distinct cell lineage and are 
defi ned by their production of IL-17. They play an important role in mucosal 
barriers and they stimulate neutrophils to destroy extracellular pathogens. 
Follicular helper T cells (Tfh cells) are a specialised subset of T helper 
cells that help B cells to produce antibodies (Crotty 2014). They are found 
in the lymph nodes, spleen and tonsils and they have an essential role in 
promoting germinal center formation and affi  nity maturation. Tfh cells 
are characterised by stable expression of transcription factor Bcl-6 (B 
cell lymphoma 6) and the cell surface markers CXCR5 (C-C chemokine 
receptor 5), PD-1 (programmed death 1 receptor) and ICOS (inducible 
T-cell costimulatory). ICOS-L and IL-6 promote commitment to the Tfh 
lineage. 
Regulatory T cells are characterised by the expression of the forkhead/
winged-helix transcription factor FOXP3 and they maintain peripheral 
tolerance by suppressing other lymphocytes and harmful immune responses.
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Figure 1. Cytotoxic CD8 T cell and the subsets of CD4 eff ector T cells. 
CD4 helper T cells diff erentiate into distinct subsets in response to the 
cytokine environment. The characteristic transcription factors are shown 
inside the cells. Activated helper T cells produce cytokines and enhance the 
functions of other cells. 
1.1.2 CD8 lymphocytes
CD8 T cells recognise antigens produced by cancer cells and intracellular 
viruses. Recognition of an antigen on the MHC I causes CD8 lymphocyte 
to kill the infected or malignant cell. They use death receptor Fas (CD95) 
- Fas ligand (CD95L) interaction, perforin and granzymes to induce 
apoptosis. Perforin creates pores on the infected target cells and allows 
the granzymes A and B to enter the cell. Similarly to CD4 helper T cells, 
naive CD8 cells require activation by specialised antigen-presenting cells 
before their diff erentiation into cytotoxic CD8 cells. Successful CD8 T cell 
activation also requires a preceding interaction between the APC and the 
activated CD4 helper T cell. CD8 T cell proliferation is enhanced by IL-2, 
produced by CD4 helper T cells. 
Regulatory FOXP3+ CD8 T cells have also been detected in the peripheral 
blood but their specifi c involvement remains unclear. They also express 
other Treg-associated markers CD25, GITR (glucocorticoid-induced tumor 
necrosis factor receptor) and CTLA-4 (cytotoxic T-lymphocyte-associated 
protein 4) and are identifi ed by the expression of CD103 (Cosmi, Liotta et 
al. 2003) (Uss, Rowshani et al. 2006). They can suppress activated T cells 
via cell-to-cell contact and produce IL-10 (Smith and Kumar 2008).  
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1.2 T cell receptor structure
T cell receptors expressed by αβ T cells are heterodimeric proteins that 
consist of two polypeptide chains, α and β, that both contain one variable 
(V) and one constant (C) domain. The chains are linked by a disulphide 
bond. α and β chains each have three hypervariable complementarity-
determining regions (CDR1, CDR2 and CDR3) of which the third region 
is the most polymorphic and takes the main role in recognising the peptide. 
Hypervariable CDR3 is generated by somatic recombination machinery that 
rearranges the non-contiguous Vβ, Dβ and Jβ gene segments in the β chain 
locus and Vα and Jα gene segments in the α chain locus. P- (palindromic) 
and N- (nontemplated) nucleotides are added and deleted at the Vβ-Dβ, 
Dβ-Jβ and Vα-Jα junction sites. 
CDR1 and CDR2 derive from germ-line sequences and they bind mainly 
to the major histocompatibility complex (MHC) molecule whereas 
hypervariable CDR3 recognises the displayed peptide. However, all three 
CDRs can contact both peptide and MHC. The V domain in the α chain 
contacts the amino-terminal half of the displayed peptide while the Vβ 
domain contacts the carboxy-terminal half of the peptide (Hennecke and 
Wiley 2001). X-ray crystallography has shown the three-dimensional 
structure of TCR. It has a relatively fl at ligand-binding surface for pMHC 
interaction (Wang and Reinherz 2012).
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Figure 2. T cell receptor. T cell receptors consist of two polypeptide 
chains, α and β, that both contain one variable (V) and one constant (C) 
domain. α and β chain genes are composed of non-contiguous segments 
that are rearranged by somatic recombination machinery during T cell 
development.
1.3 Co-receptors
The formation of the immunological synapse creates the interface between 
a TCR and the presenting MHC molecule on the surface of the target 
cell and the formation requires coreceptors CD3, CD4 or CD8 and other 
costimulatory molecules. TCRs are associated on the cell surface with four 
CD3-subunits (gamma, delta, epsilon, zeta) that form the CD3 protein 
which has an essential role in signal transduction. Each of them consists of 
an extracellular Ig-like domain, a short stalk region connecting peptide, a 
transmembrane helix and a cytoplasmic tail. TCR-peptide-MHC interaction 
induces a cascade of downstream signalling events via the ITAMs 
(immunoreceptor tyrosine-based activation motifs) in the cytoplasmic tail 
of the CD3 (Wang and Reinherz 2012). 
The co-receptors CD4 and CD8 are essential in TCR-pMHC-interaction 
since they contact the MHC, stabilise this interaction and increase its duration 
(Das, Sheridan et al. 2001). CD4 is composed of four immunoglobulin-like 
21
domains and it binds MHC II molecule with the fi rst domain. TCR-pMHC 
interaction initiates downstream signalling events when CD4 delivers the 
tyrosine kinase Lck (lymphocyte-specifi c protein tyrosine kinase) into close 
proximity with the complex and allows the phosphorylation of ITAMs and 
the recruitment of Zap-70 (Wang and Reinherz 2012). 
CD8A and CD8B genes encode the chains of the CD8 co-receptor. Each 
chain contains a single immunoglobulin-like domain that is linked to a 
glycosylated polypeptide chain. The isoform CD8ab is the most common 
but CD8a chains can also form a homodimer. CD8 binds the α3 domain 
of the MHC I molecule and also recruits Lck with the cytoplasmic tail to 
bring it into close proximity with the TCR-complex leading to downstream 
signalling events (Wang and Reinherz 2012).
1.4 Antigen recognition and MHC interaction
T cells recognise foreign antigens through presentation of antigen peptides 
by MHC molecules on the cell surface. There are more than 200 MHC 
genes located in chromosome 6 in humans. MHC class I and II proteins in 
humans are called human leukocyte antigens (HLA) and many autoimmune 
diseases are associated with a certain HLA allele. The HLA genes are 
HLA-A, -B and -C in MHC I and HLA-DP, -DQ and -DR in MHC II. 
One α-β superdomain and two immunoglobulin-like domains form a 
heterodimer in the MHC molecule. The superdomain binds the peptide and 
is composed of one heavy chain in the MHC I and two heavy chains in 
MHC II (Rudolph, Stanfi eld et al. 2006). 
MHC I displays peptides primarily derived from intracellular degradation 
of proteins in the cytosol and is expressed by all the nucleated cells. The 
pathogen antigen presented in the MHC I molecule indicates intracellular 
infection and instructs cytotoxic CD8 T cell to kill the cell. Dendritic cells, 
macrophages, thymic epithelial cells (TECs) and B cells express MHC 
II. Specialised antigen-presenting cells are dendritic cells that display 
antigens to naive T cells that activate the immune response. Dendritic 
cells (DCs) process antigens collected from tissues and convey them to 
the peripheral lymphoid organs. Presentation of antigens to naive T cells 
leads to T cell activation and immune response. Three signals are essential 
for T cell activation: TCR-pMHC-interaction, a co-stimulatory signal 
from the interaction between CD28 and CD80/CD86 and cytokines. T cell 
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activation is carefully regulated since unnecessary activation can lead to 
autoimmune reaction. Antigen presentation, the expression of costimulatory 
molecules and the availability of cytokines set limits for the activation. 
Cross-presentation allows dendritic cells to capture, process and present 
exogenous antigens on the MHC I molecule. This is essential for activating 
viral- and tumor-specifi c CD8 T cell responses (Fehres, Unger et al. 2014). 
2. REGULATORY T CELLS
2.1 Natural Regulatory T cells
Regulatory T cells have an essential role in regulating immune responses, 
maintaining immunological tolerance and preventing autoimmunity. They 
are divided into two groups: natural regulatory T cells (nTregs) that derive 
from the thymus and induced regulatory T cells (iTregs) that diff erentiate 
from conventional CD4 T cells in the periphery. Conventional CD4 T 
cells can transiently acquire the low expression of FOXP3 upon antigen 
stimulation and activation but the phenotype is not stable (Chen, Jin et al. 
2003) (Walker, Kasprowicz et al. 2003, Gavin, Torgerson et al. 2006, Allan, 
Crome et al. 2007, Nagar, Vernitsky et al. 2008). 
Regulatory T cells are characterised by the expression of the forkhead/
winged-helix transcription factor FOXP3 that regulates Treg development 
and function. Mutations in FOXP3 lead to early and severe immune 
dysregulation, polyendocrinopathy, enteropathy and X-linked syndrome 
(IPEX) in humans (Bennett, Christie et al. 2001). Defects in suppressive 
Tregs can cause numerous other autoimmune diseases in humans and 
regulatory T cells are also involved in infection and cancer (Belkaid and 
Rouse 2005, Curiel 2007, Costantino, Baecher-Allan et al. 2008). In the 
future Treg-based immune therapies have huge potential for the treatment 
of immune-mediated diseases.  
The majority of regulatory T cells present in the periphery are natural Tregs 
originating from the thymus (Hsieh, Zheng et al. 2006, Wong, Mathis et al. 
2007). In mice neonatal thymectomy after birth prevented the emergence of 
natural Tregs (Asano, Toda et al. 1996). In 1995 Sakaguchi et al. reported 
the existence of a CD4 T cell population that expressed IL-2 receptor α 
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chain (CD25) and had a suppressor function (Sakaguchi, Sakaguchi et al. 
1995). Human CD4+ CD25high Tregs were fi rst identifi ed and reported in 
2001 (Baecher-Allan, Brown et al. 2001). The expression of Foxp3 as a 
regulatory T cell marker was reported in 2003 (Fontenot, Gavin et al. 2003, 
Hori, Nomura et al. 2003). 
The constitutive expression of FOXP3 is the main feature of natural Tregs 
but the high expression of IL-2 receptor α chain (CD25) is also an important 
marker and useful in the purifi cation of Tregs. Tregs require IL-2 from other 
cellular sources since they do not produce it themselves. However, CD25 is 
also expressed by antigen-activated non-regulatory CD4 T cells in peripheral 
blood and only 1-2% of highest expressing cells are Tregs (Baecher-Allan, 
Brown et al. 2001, Sakaguchi, Miyara et al. 2010). Defi ciency of CD25 
leads to autoimmunity and immunodefi ciency in humans (Caudy, Reddy et 
al. 2007). Patients with CD25 defi ciency have normal count of  FOXP3+ 
cells but the Treg suppressive function is impaired. 
Low expression of the α chain of the IL-7 receptor (CD127) is characteristic 
of Tregs, although conventional T cells can downregulate the expression of 
CD127 upon activation (Liu, Putnam et al. 2006, Seddiki, Santner-Nanan 
et al. 2006). A homing marker CD62L, CD103, GITR and CTLA-4 are 
also associated in regulatory T cells (Seddiki, Santner-Nanan et al. 2006, 
Sakaguchi, Miyara et al. 2010). An inhibitory receptor CTLA-4 is essential 
for Treg suppressor function but it can also be expressed by activated CD4 
and CD8 T cells (Jago, Yates et al. 2004). The defi ciency of CTLA-4 causes 
severe immune dysregulation and IPEX-like phenotype (Kuehn, Ouyang et 
al. 2014, Schubert, Bode et al. 2014). 
Tregs have been studied extensively in murine models but there are 
signifi cant diff erences between human and murine Tregs and their 
developmental pathways. Human Tregs can express alternatively spliced 
FOXP3 isoforms with distinct functions (Du, Huang et al. 2008) and they 
can be divided into functionally distinct subsets (Ito, Hanabuchi et al. 2008, 
Miyara, Yoshioka et al. 2009). CD25high CD127low CD45RO+ FOXP3+ 
Tregs have the strongest suppressive capacity and antigen stimulation leads 
to their apoptosis. CD25+ CD127low CD45RA+ FOXP3low CD31- Tregs 
have lower expression of CD25 and FOXP3, weaker suppressive capacity 
and stronger resistance to apoptosis upon TCR stimulation. They are also 
highly proliferative and express CD31, which is a marker of recent thymic 
24
emigrants. It has been suggested that these cells are the predominant subset 
of Tregs that derive from the thymus, emigrate, proliferate and convert into 
eff ector Tregs (Cvetanovich and Hafl er 2010). The human Treg population 
exhibits more heterogeneity than in mice. Human terminally diff erentiated 
CD25high CD127low CD45RO+ FOXP3high Treg population is identifi ed by 
the expression of HLA-DR. They have signifi cantly higher expression of 
FOXP3 than HLA DR- eff ector Tregs, use contact-dependent suppression 
mechanisms and do not produce IL-10 (Baecher-Allan, Wolf et al. 2006, 
Costantino, Baecher-Allan et al. 2008). 
Figure 3. Treg-associated markers. 
2.2 FOXP3
FOXP3 (Foxp3 in mice) is a key distinguishing marker of regulatory T 
cells in humans and is essential for Treg suppressor function, proliferation 
and diff erentiation (Fontenot, Gavin et al. 2003, Hori, Nomura et al. 2003, 
Khattri, Cox et al. 2003, Yagi, Nomura et al. 2004, Fontenot, Dooley et al. 
2005, Fontenot, Rasmussen et al. 2005, Gavin, Rasmussen et al. 2007). A 
loss-of-function mutation in the FOXP3 gene leads to absence of Tregs and 
IPEX syndrome in humans and deletion of the Foxp3 gene leads to scurfy 
phenotype in mice (Chatila, Blaeser et al. 2000, Bennett and Ochs 2001, 
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Wildin, Ramsdell et al. 2001, Gambineri, Torgerson et al. 2003). Nowadays 
there are over 20 known FOXP3 mutations causing IPEX syndrome (Myers, 
Perroni et al. 2006). In human peripheral blood, FOXP3 expression is 
strong in the CD4+ CD25high population, while low in activated CD4 T 
cells (Wang, Ioan-Facsinay et al. 2007). The CD8 T cell subset can also 
upregulate FOXP3 expression. FOXP3 is a regulator that prevents Tregs 
from deviating into other T cell lineages. Loss of it leads to acquisition of 
eff ector T cell properties including the cytokine production of IL-2, IL-4, 
IL-17 and IFNγ (Wan and Flavell 2007, Williams and Rudensky 2007). 
Forced expression of FOXP3 allows both regulatory and conventional T 
cells to acquire a suppressive function (Aarts-Riemens, Emmelot et al. 
2008).
FOXP3 can regulate 700-1400 target genes, acting as a transcriptional 
activator and repressor in developing and established regulatory T cells. The 
target genes are essential for a functional phenotype including Ctla4, Il2ra, 
Nrp1 and Tnfrsf18 (GITR). In addition to direct binding to genomic site, 
FOXP3 controls transcription indirectly by interacting and collaborating 
with cofactors (NFAT, NF-kB). Mediating epigenetic modifi cations at 
the target gene loci has also been reported to be an important regulating 
mechanism of FOXP3. There are notable diff erences in the function of 
FOXP3 in the periphery and the thymus, where its role in FOXP3-dependent 
diff erentiation is emphasised (Zheng, Josefowicz et al. 2007). Lin et al. 
have also questioned the importance of Foxp3 in murine Treg development 
(Lin, Haribhai et al. 2007). They reported that in the absence of functional 
Foxp3, Treg maturation proceeded and mature T cells exhibited the same 
characteristics as Treg cells but lacked suppressor function. 
The human FOXP3 protein encoding gene is found in the X chromosome 
and has 11 exons (Brunkow, Jeff ery et al. 2001). The promoter area is 
activated by transcription factors NFAT (nuclear factor of activated T cells), 
AP-1 (activator protein 1) and FOXO proteins, but the most essential for 
initiation of transcription are the conserved non-coding sequences CNS1, 
CNS2 and CNS3. CNS1 is considered a TGF-β sensor element which binds 
the transcription factor SMAD3 and plays a role in the generation of induced 
Tregs. CNS2 is a completely demethylated region which ensures stable 
Treg phenotype (see below). CNS3 initiates the transcription of FOXP3 
in both natural and induced Tregs and the deletion of it reduces thymic 
Treg numbers signifi cantly. The role of TCR stimulation and cytokines is 
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important for the transcription and expression of FOXP3 (discussed further 
later). 
There are multiple variant FOXP3 isoforms that are alternatively spliced 
in humans. Their production depends on TCR activation. FOXP3∆2 lacks 
the region encoded by exon 2; FOXP3∆7 lacks exon 7 and FOXP3∆2∆7 
lacks both. The expression pattern of diff erent isoforms remains unclear 
(Ramsdell and Ziegler 2014). 
2.3 Treg function and peripheral tolerance
The mechanisms of central tolerance eliminate autoreactive T cells 
during thymic development but peripheral tolerance maintains immune 
homeostasis and prevents autoimmune reactions in the periphery. Treg 
suppressor function is crucial in mediating harmful immune reactions. 
Activated regulatory T cells suppress eff ector T cells, dendritic cells, B 
cells, NK cells and macrophages at the infection site. TCR activation of 
Tregs is required and the shared antigen specifi city between Treg and the 
target T cell might increase the effi  ciency of suppression (Corthay 2009).
Regulatory T cells produce anti-infl ammatory cytokines TGF-β, IL-10 
and IL-35, use direct cell-cell contact and modulate the antigen-presenting 
cells to suppress too potent immune reactions (Costantino, Baecher-Allan 
et al. 2008, Shevach 2009). IL-10 decreases the production of IL-2, TNF-α 
and IL-5 and inhibits the function of DCs and macrophages (Couper, 
Blount et al. 2008). Suppression through granzymes induces apoptosis in 
B cells and eff ector T cells (Zhao, Thornton et al. 2006). Tregs can also 
eliminate growth factors by taking up IL-2 from the environment of the 
eff ector cells and disturb the eff ector cell metabolism by taking up scarce 
amino acids through expression of ectoenzymes CD39 (ectonucleoside 
triphosphate diphosphohydrolase-1) and CD73 (Kobie, Shah et al. 2006, 
Borsellino, Kleinewietfeld et al. 2007). In addition, Tregs are suggested to 
regulate immune responses to infl ammation, infection and tumor growth 
(Josefowicz and Rudensky 2009). 
Tregs express co-inhibitory CTLA-4 molecules that interact with CD80/
CD86 ligands with higher affi  nity than CD28 leading to the downregulation 
of costimulatory molecules on antigen-presenting cells. This hinders the 
activation of eff ector T cells because of the lack of the second signal (Oderup, 
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Cederbom et al. 2006). Tregs can also use CTLA-4 to induce the expression 
of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase on APCs 
(Schmidt, Nino-Castro et al. 2012). LAG-3 (lymphocyte activation gene 3 
protein) expressed by Tregs binds to MHC II molecules and suppresses DC 
maturation (Liang, Workman et al. 2008). In conventional T cells LAG-3 
inhibits cellular proliferation and activation (Sega, Leveson-Gower et al. 
2014). Through galectin-1 expression Tregs can arrest cell cycle, induce 
apoptosis and inhibit cytokine production in target cells (Garin, Chu et al. 
2007). 
Producing anti-infl ammatory cytokines is a basic function of Tregs but 
recent studies have also detected a pro-infl ammatory Foxp3+ regulatory 
population (Voo, Wang et al. 2009, Dominguez-Villar, Baecher-Allan et 
al. 2011). Under infl ammatory conditions they produce pro-infl ammatory 
cytokines IFN-γ and IL-17A. Their functions have been identifi ed in various 
autoimmune diseases such as psoriasis and type 1 diabetes (Pandiyan and 
Zhu 2015). 
2.4 Epigenetic regulation of Tregs
In regulatory T cells the expression of FOXP3 alone is not suffi  cient 
for generating a stable Treg phenotype. Some Treg-specifi c genes are 
expressed in Treg cells independently of FOXP3 expression and induced 
Tregs lack a signifi cant part of the Treg signature genes (Sugimoto, Oida 
et al. 2006, Hill, Feuerer et al. 2007). Transient FOXP3 expression is also 
insuffi  cient for naive T cells to acquire suppressor function. Epigenetic 
reprogramming seems to be signifi cant for establishing Treg lineage. In 
general, epigenetic modifi cations can either silence target genes or increase 
their accessibility for transcription factors and initiate transcription. The 
mechanisms of epigenetics include DNA methylation, histone modifi cations 
and nucleosome positioning. 
The human FOXP3 locus contains the promoter region and three conserved 
non-coding regions that regulate FOXP3 expression. CNS2, also known as 
Treg-specifi c-demethylated region (TSDR), is a CpG-rich intronic enhancer 
region that is completely demethylated in natural Tregs but methylated 
in conventional T cells and activated T cells that transiently upregulate 
FOXP3 (Baron, Floess et al. 2007). In addition, there are permissive histone 
marks present at the FOXP3 promoter in Tregs (Schmidl, Klug et al. 2009). 
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The maintenance of demethylated TSDR is a marker of stable FOXP3 
phenotype (Floess, Freyer et al. 2007). In humans DNA methylation of 
TSDR mostly prevents stable transcription of FOXP3 in conventional T 
cells (Nagar, Vernitsky et al. 2008). Induced Tregs have more heterogeneous 
demethylation patterns in TSDR than natural Tregs and their phenotype 
is less stable. TSDR methylation analysis might become a useful clinical 
tool for quantitative evaluation of peripheral Tregs (Janson, Winerdal et al. 
2008). Barzaghi et al. reported that IPEX-like patients (IPEX phenotype 
caused by gene defects other than FOXP3) exhibited reduced numbers of 
Tregs using TSDR demethylation assay (Barzaghi, Passerini et al. 2012). 
The initiation of FOXP3 expression does not require the demethylation of 
TSDR but long-term stability is maintained by it (Huehn, Polansky et al. 
2009, Zheng, Josefowicz et al. 2010). The forced demethylation of TSDR 
also leads to a stable phenotype (Polansky, Kretschmer et al. 2008). In 
murine models the demethylation of TSDR was initiated during the early 
stages of thymic development, leading to the generation of stable mature 
regulatory T cells. The mechanisms included 5-hydroxymethylcytosine 
(5hmC) and enzymes of the ten-eleven-translocation (Tet) family (Toker, 
Engelbert et al. 2013). Mice defi cient of Tet2 and Tet3 have Tregs with 
unstable Foxp3 expression and they easily lose their suppressive function 
(Yue, Trifari et al. 2016). The pathways leading to demethylation of TSDR 
are only partially known. TCR signalling and downstream activation of 
the NF-kB family member transcription factor c-Rel are suggested to play 
a signifi cant role in demethylation of CNS2 resulting in the induction of 
Foxp3 (Long, Park et al. 2009, Engel, Sidwell et al. 2013). 
Studies in mice have shown that the demethylation of TSDR is essential 
during thymic Treg development (Ohkura, Hamaguchi et al. 2012, 
Kitagawa, Ohkura et al. 2015). Ohkura et al. recognised several regions 
within Treg-cell associated genes encoding proteins such as CD25, CTLA-
4, Eos and GITR that were demethylated in regulatory lineage thymocytes 
in the thymus. Foxp3 expression alone was not suffi  cient for establishing 
stable Treg lineage. TSDR hypomethylation pattern is induced by TCR 
stimulation and can occur independently of Foxp3 expression. Toker et 
al. have shown that active demethylation of TSDR occurs in parallel with 
the induction of Treg-type gene expression and was completed as Tregs 
emigrated from the thymus (Toker, Engelbert et al. 2013). The loss of 
DNA methylation was initiated by TET2 and TET3 enzymes and led to 
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the oxidation of 5-methylcytocines. Treg precursors might have epigenetic 
modulation in their chromatin structure prior to Foxp3 induction since 
they are primed to induce DNA demethylation after stimulation with TCR 
and IL-2 during their development. A global chromatin organiser, Satb1, 
was recently recognised to bind to the CNS0 region in the Foxp3 locus 
in double positive thymocytes (Kitagawa, Ohkura et al. 2017). Epigenetic 
modifi cations seem to play a role in the early stages of Treg development. 
Figure 4. Regulation of the FOXP3 gene. The FOXP3 locus contains 
the promoter region and three conserved non-coding regions that regulate 
FOXP3 expression. CNS2 is also known as Treg-specifi c-demethylated 
region (TSDR). TCR and IL-2 downstream signalling mediate the 
transcription of FOXP3. The transcription factors binding to the promoter 
and CNSs are shown above the fi gure.
2.5 Induced Tregs
Natural regulatory T cells are the main regulatory population in the periphery 
but naive CD4 T cells are also able to upregulate FOXP3 and diff erentiate 
into induced Tregs (iTregs). FOXP3 induction requires TCR signalling with 
appropriate cytokines, including transforming growth factor β (TGF-β) and 
interleukin-2 (Chen, Jin et al. 2003, Zheng, Wang et al. 2004, Kretschmer, 
Apostolou et al. 2005, Davidson, DiPaolo et al. 2007, Selvaraj and Geiger 
2007, Horwitz, Zheng et al. 2008). Mice defi cient of TGF-β1 exhibit 
normal Treg development in the thymus but in the periphery the number 
of Tregs are decreased (Marie, Letterio et al. 2005). There is evidence that 
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TCR specifi city dictates FOXP3 induction (Lathrop, Santacruz et al. 2008) 
and functionally specialised dendritic cells are able to induce iTregs more 
effi  ciently (Coombes, Siddiqui et al. 2007, Maldonado and von Andrian 
2010). Guo et al. have suggested a two-step iTreg diff erentiation in murine 
models. CD4+ CD25+ Foxp3+ iTregs precursors were generated by TCR 
activation and inhibition of IL-2 signalling. Exposure of these peripheral 
iTreg precursors to IL-2 led to Foxp3 expression via Stat5 phosphorylation 
(Guo, Khattar et al. 2013).  
iTreg diff erentiation is mainly associated with bacterial or viral infections, 
tumors and oral tolerance in mucosal tissues. They are enriched in 
the intestine and maternal placenta and they play an essential role in 
maintaining immune homeostasis there (Hadis, Wahl et al. 2011, Samstein, 
Josefowicz et al. 2012).  In the gut the availability of TGF-β and retinoid 
acid contributes to the induction of Tregs (Coombes, Siddiqui et al. 2007). 
Both nTregs and iTregs feature Treg-associated markers CD25, GITR, 
CTLA-4 and CD103 but there are diff erences in the expression of PD-1, 
neuropilin-1 (Nrp1), Helios and CD73 (Yadav, Louvet et al. 2012). Natural 
Tregs have stronger suppressive capacity than iTregs and iTregs act more 
locally in mucosal barriers. The overlap in TCR repertoire between iTregs 
and conventional T cells is restricted (Yadav, Stephan et al. 2013). Signifi cant 
diff erence between thymus-derived natural Tregs and iTregs is the stability 
of the phenotype. iTregs are unstable because of the methylated TSDR in 
the CNS2 region. In human studies the in vitro conversion of iTregs from 
conventional T cells is less effi  cient than in mice. Induced Tregs easily lost 
FOXP3 expression, were not suppressive and produced proinfl ammatory 
cytokines. In murine models TGF-β alone has not been suffi  cient to 
generate a stable demethylated TSDR and regulatory phenotype for 
iTregs but administration of IL-2 together with TCR stimulation enhanced 
demethylation (Chen, Kim et al. 2011).  
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3. T CELL DEVELOPMENT
3.1 The structure of the thymus
T cell precursors derive from the bone marrow but migrate to the thymus 
during the early stage of development. The thymus is situated in the 
mediastinum in front of the heart and is divided structurally into the 
cortex and medulla. Thymic stroma provides the proper environment for 
thymocyte maturation. The most active phase of the thymus is during 
the neonatal period and childhood but the production of T cell continues 
throughout adult life. The thymus gradually atrophies and is replaced with 
adipose tissue with age. 
The cortex includes immature thymocytes, branched cortical epithelial cells 
and macrophages that clear apoptotic thymocytes. Proliferating immature 
thymocytes are situated in the outer cortical layer before they migrate to the 
deeper cortical layer for thymic selection. Cortical thymic epithelial cells 
(cTECs) form a complex reticular network of stromal cells, supporting 
early and later stages of T cell development. The Notch ligand Delta-like 4 
expressed by cTECs promotes the formation of double positive CD4+CD8+ 
thymocytes (Hozumi, Mailhos et al. 2008, Koch, Fiorini et al. 2008). 
The medulla contains mature thymocytes, medullary epithelial cells, 
macrophages, dendritic cells and Hassall’s corpuscles. Especially medullary 
thymic epithelial cells have a signifi cant role in T cell development and can 
express tissue-specifi c-antigens that engage in negative selection. There 
are three diff erent kinds of thymic dendritic cells, resident classical DCs, 
migratory classical DCs and migratory classical plasmacytoid DCs. Thymic 
nurse cells (TNCs) are comprised of multicellular complexes formed by 
cortical epithelial cells. 
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Figure 5. The structure and the cells of the thymus. The thymus is 
divided into a central medulla and an outer cortex. Precursor thymocytes 
enter the thymus via large blood vessels at the corticomedullary junction 
(CMJ). Double-negative (DN) thymocytes become double-positive (DP) 
thymocytes in the cortex and undergo positive selection mediated by 
cortical thymic epithelial cells (cTECs). Positively selected DP thymocytes 
diff erentiate into CD4+ or CD8+ single-positive (SP) thymocytes and 
migrate to the medulla.
 
3.2 T cell precursors
The precursor cells derive from hematopoietic stem cells (HSC) in the bone 
marrow and migrate via the bloodstream to the thymus. Thymus seeding 
progenitors (TSP) that express CD34+ CD45RA+ CD7+ enter through 
large venules at the border of the cortex and the medulla (corticomedullary 
junction CMJ). CD34+ CD38low early thymic progenitors (ETPs) occupy 
the outer cortex. The number of T cell precursor cells in the peripheral 
blood is extremely small (Krueger and von Boehmer 2007, Krueger, 
Zietara et al. 2017). Interaction with the thymic stromal cells triggers T 
cell diff erentiation. Notch1 is a transcription factor that has been identifi ed 
as being essential in the commitment to diff erent cell lineages. Sustained 
Notch signalling instructs thymocytes to commit to T cell lineage and lack 
of it leads to the arrest of T cell development in mice (Blom and Spits 
2006). 
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Before commitment to T cell lineage ETPs lack the expression of RAG1 
(recombination activating gene 1), CD1A, and cytoplasmic CD3, CD2 
and CD7. The committed thymocytes express CD34, CD1a, CD7 and IL-
7Ra. IL-7 has been shown to be essential for thymocyte development and 
survival at the early stage. During early development CD34+ thymocytes 
proliferate in response to IL-7. IL-7-defi cient mice have reduced numbers 
of αβ T cells and lack γδ T cells and in humans IL-7R-defi cient patients 
exhibit a severe combined immunodefi ciency (SCID-X1) (von Freeden-
Jeff ry, Vieira et al. 1995, Bayer, Lee et al. 2008).
3.3 T cell development at the double negative stage
The development of thymocytes is divided into distinct phases that refl ect 
the changes in the status of T cell receptor chains and in the expression of 
CD3 and co-receptors CD4 and CD8 on the cell surface. The commitment to 
the αβ or γδ T cell lineage takes place during early thymocyte development. 
TCR signal strength is essential for the lineage choice between αβ and γδ 
T cells. A strong TCR signal leads to γδ while a weak signal leads to αβ 
lineage commitment. In humans there are three distinct double negative 
stages: the most immature CD34+ CD38- CD1a-, CD34+ CD38+ CD1a-, 
and CD34+ CD38+ CD1a+. 
Notch signalling promotes thymocyte proliferation and diff erentiation at 
the double negative stages. In mice, early thymic progenitors express a 
CD4- CD8- CD44+ CD25- CD117+ phenotype (Allman, Sambandam et 
al. 2003) and the double negative stage is subdivided into four stages based 
on the expression of CD44 and CD25. In the early DN1 phase thymocytes 
express the phenotype of CD44+ CD25- and the DN1 stage can be further 
subdivided on the basis of CD24 and CD117. The transcription factor 
Bcl11b is essential for T cell lineage commitment at the DN2 (CD44low 
CD25+) stage. The somatic recombination of the TCRβ genes V, D and J 
is also initiated at the DN2 phase by recombination activating genes RAG1 
and RAG2. In humans TCRβ rearrangement starts at the CD34+ CD38+ 
CD1a- stage (Dik, Pike-Overzet et al. 2005). 
3.3.1 Recombination of TCR genes
TCR diversity is generated by somatic rearrangements of the non-contiguous 
Vβ, Dβ and Jβ gene segments in the β chain locus and Vα and Jα gene 
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segments in the α chain locus. These multiple gene segments allow somatic 
recombination to encode a huge number of unique TCR sequences. To 
increase diversity, P- (palindromic) and N- (nontemplated) nucleotides are 
added and deleted at the Vβ-Dβ, Dβ-Jβ and Vα-Jα junction sites (Krangel 
2009). Terminal deoxynucleotidyl transferase (TdT) is a DNA polymerase 
expressed in DN thymocytes that adds N-nucleotides at the junction sites. 
Theoretical diversity produced by the recombination machinery is huge, 
with over 1015 αβ receptors (Davis and Bjorkman 1988). The pairing of α 
and β chains that forms the TCR heterodimer, increases the diversity. TCRδ 
and TCRγ rearrange fi rst before TCRβ and the commitment to TCRαβ 
lineage take place. Only a few γδ T cells have a rearranged TCRβ chain but 
TCRγ genes are rearranged in most TCRαβ cells (Sherwood, Desmarais et 
al. 2011).  
β selection is the fi rst major checkpoint in T cell development and in humans 
it takes place at the CD34+ CD38+ CD1a+ stage (Dik, Pike-Overzet et al. 
2005). In mice it follows the somatic recombination of the TCR β locus at 
the DN3 (CD44-, CD25+) stage and terminates the β rearrangements. The 
selection ensures that thymocytes have a functional β chain on their surface 
and ends β-chain rearrangement, leading to allelic exclusion of the β locus 
(Khor and Sleckman 2002, Nishana and Raghavan 2012). A functional 
TCRβ gene must be assembled on only a single allele. Both alleles should 
not attempt VDJ recombination at the same time and a successful in-frame 
recombination on one allele gives a feedback signal that prevents further 
recombination events. Thymocytes with out-of-frame TCRβ chains do not 
pass the β selection and go to apoptosis. The successfully rearranged β chain 
allows the expression of pre-TCR, cell proliferation, and diff erentiation 
into DN4 stage. Signalling through IL-7 receptors ensures the survival of 
DN thymocytes. 
3.4 The double positive stage
DN4 (CD44- CD25-) thymocytes become immature single positive (Petrie, 
Livak et al. 1993) CD4+ cells that have acquired the expression of CD4 
but not yet CD8. The CD4ISP stage is followed by the expression of only 
CD8 α chain before the cells acquire both α and β chains. The expression 
of CD3-pre-TCR complex leads to cell proliferation, allelic exclusion 
and progression towards the double positive CD4+ CD8+ stage (Michie 
and Zuniga-Pfl ucker 2002). DP thymocytes comprise the majority of the 
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thymic population. The DP phase can be subdivided into diff erent stages 
based on TCR-CD3 expression. At the early DP stage thymocytes lack 
CD3 expression but start to express it at the DP CD3low stage. After positive 
selection high expression of CD3 can be detected (Vandekerckhove, 
Barcena et al. 1994). CD69 is a C-type lectin-like signalling receptor that 
is a marker of positive selection (Sancho, Gomez et al. 2005). Most of 
the thymocyte proliferation during thymic development occurs during the 
late DN and early DP stages (Egerton, Scollay et al. 1990, Scollay and 
Godfrey 1995, Porritt, Gordon et al. 2003). In more mature DP populations 
the proliferation rate is low (Egerton, Scollay et al. 1990, Sinclair, Bains et 
al. 2013). In humans only 1-2 divisions were reported between DP CD3low 
stage and mature CD4SP and CD8SP thymocytes (Okamoto, Douek et al. 
2002). 
3.4.1 Rearrangement of the TCRα chain
The rearrangement of the α chain locus can pass through multiple attempts 
without allelic exclusion to achieve a functional TCR. The rearrangement 
initiates after cell proliferation, when thymocytes express both pre-TCRα 
and TCRβ at the CD34+ CD38+ CD1a+ stage (Dik, Pike-Overzet et al. 
2005). In the α locus only V and J gene regions are rearranged and the 
process can be repeated until thymocytes acquire a functional α chain and 
can survive positive selection or are selected to die by neglect. On average 
fi ve rounds of VJ recombination have been suggested on each allele 
(Warmfl ash and Dinner 2006). 
Some thymocytes (approximately 30% of conventional thymocytes) can 
express two TCRs, consisting of two diff erent α chains pairing with the same 
β chain. This is due to poor α chain allelic exclusion (Padovan, Casorati et 
al. 1993, Petrie, Livak et al. 1993). Dual TCR expression provides two 
distinct pMHC ligand specifi cities and a survival advantage in positive 
selection. During negative selection it can mask autoreactive TCRs from 
elimination. Mice defi cient in secondary TCRs exhibited reduced numbers 
of thymocytes that survived positive selection, suggesting that simultaneous 
rearrangement of both TCRα loci is required for effi  cient T cell generation 
(Ni, Solomon et al. 2014). In the regulatory T cell population between 50% 
and 99% express two TCRs (Tuovinen, Salminen et al. 2006).
36
Figure 6. T cell development and thymic selections. The development 
of thymocytes is divided into distinct phases that refl ect the changes in 
the status of T cell receptor chains and in the expression of CD3 and co-
receptors CD4 and CD8 on the cell surface. DN thymocytes lack both 
CD4 and CD8 co-receptors. TCRβ recombination is initiated at the DN 
phase. DN thymocytes become immature single positive CD4+ cells. The 
expression of CD3-pre-TCR complex leads to cell proliferation, allelic 
exclusion and progression towards the double positive CD4+ CD8+ stage. 
The DP phase can be subdivided into diff erent stages based on the TCR-
CD3 expression. At the early DP stage thymocytes lack CD3 expression 
but start to express it at the DP CD3low stage. After positive selection high 
expression of CD3 can be detected. TCRα rearrangement occurs at the DP 
stage and can pass through multiple attempts. 
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3.5 Positive selection
Together, positive and negative selection eliminate over 90% of all 
thymocytes. The selections are dictated by TCR signalling strength and the 
peptide ligand pool composed primarily of self-peptides (Starr, Jameson 
et al. 2003). Thymic epithelial cells display these self-antigens complexed 
with MHC on their cell surface and mediate positive selection. The pathways 
that cTECs use to generate the diverse repertoire of selecting ligands 
include cathepsins, thymic-specifi c serine proteases, macroautophagy and 
thymoproteasome (Klein, Hinterberger et al. 2009). The peptides mediating 
positive selection are mainly low-affi  nity antagonists (ligands that block 
response) and weak agonists (ligands that have only partial effi  cacy).
According to the TCR affi  nity model the quality of the TCR-peptide-MHC 
interaction dictates whether a thymocyte survives positive selection or dies 
by neglect. The affi  nity threshold determining the outcome of the selection 
has been shown to be remarkably narrow. The affi  nity between TCR and 
self-peptide-MHC-complex must be suffi  cient to prevent the apoptosis of 
the cell in positive selection. This ensures that the developing thymocytes 
are capable of recognising peptide-MHC complexes with their TCR. A 
minimal signal is required for cell survival. Most T cells at this stage are 
eventually not able to bind to MHC and die by neglect. Co-receptors CD4 
and CD8 ensure a stable binding in the TCR-pMHC interaction (Germain 
2002). Themis (thymocyte-expressed molecule involved in selection) is one 
of the molecules modulating TCR signalling during selection (Fu, Vallee 
et al. 2009, Johnson, Aravind et al. 2009). It can reduce TCR signalling 
strength and selection threshold in response to low affi  nity MHC peptides. 
Themis is expressed predominantly at the early DP stage and the expression 
decreases after positive selection. Mice defi cient of Themis exhibit a defect 
in positive selection and have reduced numbers of SP thymocytes and 
peripheral T cells (Gascoigne, Rybakin et al. 2016). 
T cells respond to foreign antigens displayed by cells expressing a 
particular MHC which is called MHC restriction. Positive selection is a 
mechanism to ensure that the recognised antigen must be presented by the 
MHC molecule. Germline encoded CDR1 and CDR2 primarily bind the 
MHC molecule in the TCR-pMHC complex and it has been suggested that 
co-evolution of TCR and MHC favours TCRs capable of binding MHC 
molecules. The selection model is based on the role of co-receptors CD4 
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and CD8 in regulating MHC restriction (Rangarajan and Mariuzza 2014). 
After positive selection CD69+ double positive thymocytes diff erentiate 
into CD4 or CD8 single positive cell lineage. TCR signalling regulates 
the lineage commitment. The partial downregulation of CD8 allows the 
thymocytes to choose whether its TCR is MHC I or MHC II restricted. 
Sustained TCR-MHC II signalling instructs thymocytes to commit to CD4 
lineage but the recognition of MHC I leads to CD8 upregulation (Singer, 
Adoro et al. 2008). The migration to the medulla is regulated by cortical 
retaining and medullary attractant signals. Thymocytes upregulate CCR4 
that leads them to CCL17 and CCL22-producing DCs (Hu, Lancaster et al. 
2015). The chemokine receptors CCR7 and CCR9 also guide the migration. 
3.6 Negative selection
Negative selection can occur simultaneously with positive selection in 
the cortex or after the cell migration to the medulla. It induces apoptosis 
in the thymocytes, recognising self-antigens with too high affi  nity. The 
expression of self-peptides derived from diff erent tissues is required in 
the thymus to generate effi  cient negative selection. The elimination of 
autoreactive T cells maintains central tolerance. During negative selection 
between 3% and 30% of thymocytes are removed (Merkenschlager, Graf 
et al. 1997, van Meerwijk, Marguerat et al. 1997, Daley and Smith 2013, 
Stritesky, Xing et al. 2013). Medullary thymic epithelial cells (mTECs) are 
identifi ed as the main intrathymic source of promiscuous gene expression 
and the autoimmune regulator (Aire) gene controls the expression of 
tissue-restricted antigens (TRAs) in the thymus (Anderson, Venanzi et al. 
2002, Kisand, Boe Wolff  et al. 2010). Aire can also mediate the maturation 
of mTECs. Conventional dendritic cells in the thymus can also capture 
the antigens released by mTECs and present them to T cells undergoing 
selections. Migratory DCs play a role in presenting peripheral self-antigens 
that are not included in the ligand repertoire of TRAs expressed by mTECs 
(Klein, Hinterberger et al. 2009). 
The selection process creates a diverse TCR repertoire that is able to 
recognise a large array of peptides but is non-responsive to self-antigens. 
The mature single positive (SP) T cells emigrate from the thymus via 
post-capillary venules to the peripheral blood. They express sphingosine 
1-phosphate receptor 1 (S1P1), mediating the export from the thymus 
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(Kurobe, Liu et al. 2006). CD69 can inhibit the emigration of mature 
single positive thymocytes to the periphery (Feng, Woodside et al. 2002). 
Recent thymic emigrants (RTEs) lose the expression of CD69 and CD1A 
but express high levels of CD3, CD27, CD45RA, CD62L and CD31. TCR 
excision circles (TRECs) formed during TCR rearrangement are molecular 
markers that identify RTEs. 
3.7 Central tolerance
A diverse TCR repertoire is required to protect the body against potential 
pathogens but also has to maintain tolerance to prevent autoimmune 
reactions. Central tolerance eliminates autoreactive T cells via negative 
selection during thymic development. However, there are inevitably some 
autoreactive T cells that manage to avoid negative selection and emigrate 
from the thymus. Peripheral tolerance and the generation of regulatory 
T cells in the thymus compensate the faults of the central tolerance. 
Genetic mutations such as AIRE mutation in APECED (autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy) that disturb the 
central tolerance in the thymus lead to autoimmune diseases. 
3.8 TCR repertoire and diversity
The human T cell repertoire is established in the thymus. It has to protect 
the body against pathogens and maintain tolerance to self-antigens. The 
ability to recognise a huge number of potential foreign pathogens demands 
an enormous T cell receptor diversity. The majority of the TCR repertoire 
generated by somatic recombination is deleted during the selection process 
in the thymus (Bouneaud, Kourilsky et al. 2000). The shaping of the 
repertoire maintains central tolerance and prevents autoimmune reactions. 
The length of CDR3 shortens during thymic development when thymocytes 
pass through selections. Short near-germline CDR3 regions can be favoured 
by positive selection because of the more eff ective interaction with pMHC-
complexes (Yassai, Ammon et al. 2002). 
As previously described, the theoretical ability of the VDJ recombination 
machinery to create diversity is huge, with over 1015 diff erent αβ receptors 
(Davis and Bjorkman 1988, Murugan, Mora et al. 2012, Sewell 2012, 
Zarnitsyna, Evavold et al. 2013). Robins et al. have calculated the 
theoretically possible TCRβ diversity to be 5x1011 (Robins, Srivastava et 
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al. 2010). The amount of distinct clonotypes depends on the number of 
TCR α chains that each β chain combines with. The theoretical upper limit 
of peripheral TCR repertoire has been estimated to range from 1012 to 1013 
(Arstila, Casrouge et al. 1999, Nikolich-Zugich, Slifka et al. 2004). 
However, the relationship between potential and actual TCR diversity 
requires further investigation because only a fraction of the potential 
repertoire can be found in each individual at a certain time point. 1015 T 
cells would weigh around 500 kg (Mason 1998). There are 4x1011 T cells 
circulating in the adult human body (Jenkins, Chu et al. 2010) and each 
T cell has many usually identical TCRs on its surface (Varma 2008). The 
group of T cells with a similar TCR defi nes a clonotype. In the periphery the 
number of diff erent clonotypes depends on the balance between T cell loss 
and thymic input and the mechanisms controlling cell division and death 
(De Boer and Perelson 1997, Goldrath and Bevan 1999, Rudd, Venturi 
et al. 2011). Clonotypes compete for space and for stimuli from peptides 
presented by MHC molecules. Lythe et al. calculated the total number of 
clonotypes to be 1010 in the periphery (Lythe, Callard et al. 2016). They also 
suggest a mean clonal size only of order 10 even though some clonotypes 
may expand to thousands.
High-throughput sequencing has enabled the identifi cation of large numbers 
of TCRs in one sample but the entire repertoire of one individual cannot be 
directly measured. Unseen species estimators are required to estimate the 
actual diversity from one blood sample (Laydon, Bangham et al. 2015). 
Rarefaction curves developed by Daley and Smith measure the number of 
observed unique TCRβ sequences as a function of the number of sequenced 
cells and the curves saturate when the complete diversity has been sampled 
(Daley and Smith 2013). Estimator DivE also uses rarefaction curves but 
fi ts a large number of functions to the curves and scores each with 4 criteria 
that measure the accuracy and consistency of fi ts to data and subsamples 
(Laydon, Melamed et al. 2014). The fi nal estimate is the geometric mean 
of the fi ve best models. In contrast to previous estimators, non-parametric 
Chao2 is based on the overlap of TCR sequence incidence data (Chao 
1987). 
3.8.1 TCR diversity in human peripheral blood
 
The earliest estimates of the TCR repertoire in human peripheral blood were 
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done using immunoscope techniques (Even, Lim et al. 1995, Pannetier, 
Even et al. 1995). Arstila et al. measured hundreds of sequences in blood 
and extrapolated the diversity to 1 million diff erent TCRβ sequences and 
0.5x105 TCRα sequences (Arstila, Casrouge et al. 1999). In the highly 
diverse repertoire each β chain paired on average with at least 25 diff erent 
α chains. In the memory subset, the diversity decreased to 200 000 diff erent 
β chains each pairing with only a single α chain. Later Klarenbeek et al. 
observed that the memory subset is very diverse and comprises a large 
number of low-frequency clonotypes (Klarenbeek, Tak et al. 2010). 
Next generation sequencing (NGS) has made possible greater sequencing 
depth and more accurate quantifi cation of TCRs from single individuals. 
Using NGS Warren et al. calculated 1 million diff erent TCRβ sequences 
from one adult blood donor (Warren, Freeman et al. 2011) and Robins et 
al. determined the number of unique TCRβ sequences to be 3 million in 
the peripheral blood of a healthy donor (Robins, Campregher et al. 2009). 
These reports place a lower limit on directly measured diversity. In a recent 
article Qian Qi et al. used high-throughput sequencing and Chao2 estimator 
to estimate 100 million unique TCRβ sequences in naïve CD4 and CD8 T 
cell repertoires of young adults (Qi, Liu et al. 2014). Practical and ethical 
considerations set limitations on obtaining large numbers of T cells from 
healthy donors; thus detecting rare clonotypes in low frequencies remains 
challenging. 
Public T cells are T cell clonotypes that have identical TCRs and are shared 
among individuals. In theory, the likelihood of recombination machinery 
randomly generating identical TCRs should be extremely small but studies 
have shown that public T cells are quite common (Robins, Srivastava et 
al. 2010, Venturi, Quigley et al. 2011, Murugan, Mora et al. 2012). Warren 
et al. have reported that as much as 14% of an individual’s repertoire is 
comprised of public sequences (Warren, Freeman et al. 2011). Public 
clonotypes have on average fewer junctional insertions, which indicates that 
the recombination machinery or selection process is biased toward near-
germline sequences (Venturi, Kedzierska et al. 2006). Multiple nucleotide 
sequences can often encode the same public TCR amino acid sequence. 
Venturi et al. have proposed that public T cells are produced by convergent 
recombination: recombination machinery converge the production of the 
same nucleotide sequence and multiple nucleotide sequences converge to 
encode the same amino acid sequence (Venturi, Price et al. 2008). 
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4. REGULATORY T CELL DEVELOPMENT IN THE 
THYMUS
The majority of regulatory T cells arise in the thymus as a distinct T cell 
lineage, and therefore are referred to as natural Tregs. The signifi cance of 
thymus in the production of Tregs was described in a study comparing 
Treg compartments in donors’ thymus and blood samples. There was a 
direct correlation between the sizes of these two compartments (Machnes-
Maayan, Lev et al. 2015). In the human fetus mature T cells are fi rst 
detected in the thymus in the 12th gestational week and regulatory T cells 
can also be found at this stage (Cupedo, Nagasawa et al. 2005, Darrasse-
Jeze, Marodon et al. 2005, Haddad, Guimiot et al. 2006, Michaelsson, Mold 
et al. 2006, Farley, Morris et al. 2013). Fetal human Tregs are capable of 
suppression and express FOXP3, CTLA-4 and GITR (Cupedo, Nagasawa 
et al. 2005, Darrasse-Jeze, Marodon et al. 2005).
Treg development in the thymus has been extensively studied in murine 
models but in humans the developmental pathway remains only partially 
known. There are notable diff erences between human and murine Treg 
development, including for example the timing of commitment. In the 
thymus Treg diff erentiation requires TCR signalling, co-stimulatory 
molecules and common γ chain cytokines. A two-step-model based on 
the murine models suggests that TCR signalling induces the expression 
of CD25 and thus allows the cytokines to promote Treg development 
(Burchill, Yang et al. 2008, Lio and Hsieh 2008). 
4.1 Timing of commitment
During thymic development the fi rst FOXP3+ cells can be detected in the 
CD4-CD8- double negative (DN) thymocyte subset before the expression 
of TCR (Tuovinen, Kekalainen et al. 2008, Liu, Li et al. 2014). The main 
population expressing Treg markers FOXP3 and CD25 comprises mature 
CD4 single positive thymocytes but this population can also be found at 
the DP and CD8SP stages. Most FOXP3+ cells localise in the medullary 
region (Annunziato, Cosmi et al. 2002, Cosmi, Liotta et al. 2003, Cupedo, 
Nagasawa et al. 2005, Darrasse-Jeze, Marodon et al. 2005, Liotta, Cosmi 
et al. 2005, Watanabe, Wang et al. 2005, Tuovinen, Pekkarinen et al. 2008, 
Martin-Gayo, Sierra-Filardi et al. 2010, Nunes-Cabaco, Caramalho et al. 
2011). The majority of FOXP3+ CD4SP compartments develop Tregs in 
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the fi nal stage but a proportion consists of recirculating activated peripheral 
Tregs (Thiault, Darrigues et al. 2015). 
The generation of Foxp3-GFP (green fl uorescent protein) reporter mice 
has established that in mice the induction of Foxp3 occurs at the CD4SP 
stage in the thymic medulla (Fontenot, Rasmussen et al. 2005). A small 
share of GFP+ cells are also detected in DP and CD8SP populations. 
Liston et al. have suggested that DP Foxp3+ subset could comprise as 
much as one fourth of the whole regulatory population, and they also seem 
to be positively selected and express CCR7 (Liston, Nutsch et al. 2008). 
Commitment to Treg lineage might not require the expression of Foxp3 
so the lineage choice could precede the induction of Foxp3 in the cortex 
(Gavin, Rasmussen et al. 2007, Lin, Haribhai et al. 2007).
Although in murine models commitment to the Treg lineage takes place 
at the CD4+ single-positive (SP) stage, the evidence in humans suggests 
an earlier point of divergence at the CD4+ CD8+ double positive stage. 
A DP FOXP3+ population is clearly detected in the human thymus and 
they express a host of Treg-associated molecules, including CD25, CD39, 
GITR and CTLA-4, and exhibit suppressive capacity (Cupedo, Nagasawa 
et al. 2005, Darrasse-Jeze, Marodon et al. 2005, Liotta, Cosmi et al. 
2005, Nunes-Cabaco, Caramalho et al. 2011). The majority of them are 
functionally mature and positively selected since they express high levels 
of CD3 and CD69 (Tuovinen, Pekkarinen et al. 2008, Lehtoviita, Rossi et 
al. 2009). Moreover, linear regression models reported by Nunes-Cabaco et 
al. indicate that the FOXP3+ DP population is the major contributor to the 
FOXP3+ CD4 SP subset (Nunes-Cabaco, Caramalho et al. 2011). Based 
on their computational analysis, Bains et al. suggest that an induction of 
Treg development and commitment occurs at the DP phase in the cortex 
(Bains, van Santen et al. 2013). The thymic cortex is capable of supporting 
Treg development in mice, too. The block of migration from the cortex to 
the medulla leads to an accumulation of CD4SP Foxp3+ thymocytes in the 
cortex (Liston, Nutsch et al. 2008, Cowan, Parnell et al. 2013). A similar 
eff ect was reported in the case of CCR7-defi cient mice (Kurobe, Liu et al. 
2006). 
4.2 T cell receptor signalling
TCR signalling, including functional avidity and duration, dictates T cell 
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development, lineage choice to CD4 and CD8 subsets and diff erentiation 
of specialised T cell populations. The commitment to regulatory lineage 
is also dependent on TCR-mediated signalling, which is well established 
in murine models (Simons, Picca et al. 2010, Josefowicz, Lu et al. 2012, 
Kraj and Ignatowicz 2018). In negative selection developing conventional 
T cells that have high TCR affi  nity interaction with self-antigen/MHC 
complexes undergo apoptosis but thymocytes receiving low affi  nity TCR 
signals pass the selection. Thymic regulatory T cells express a diverse 
TCR repertoire that is also subjected to thymic selection. TCR transgenic 
mice studies have shown that self-reactive Foxp3-expressing thymocytes 
had a survival advantage in the negative selection compared to cells that 
received equal TCR signalling but no Foxp3 (Josefowicz, Lu et al. 2012). 
The selection to Treg lineage requires intermediate-to-high TCR affi  nity 
to self-antigens complexed with MHC molecules on the surfaces of the 
epithelial cells (Aschenbrenner, D’Cruz et al. 2007). The strength of the 
TCR signal can have a direct role in driving the extent of both elimination 
of autoreactive T cells and Treg diff erentiation (Caton, Kropf et al. 2014). 
Impaired negative selection process caused by reduced expression of MHC 
II molecules in medullary epithelial cells led to increased frequency of 
Tregs (Friedline, Brown et al. 2009).
In the human thymus the markers of positive selection, CD69 and CD27, 
are found in developing Tregs and the transcription of FOXP3 is activated 
by TCR stimulation and its downstream targets NFAT and AP-1 in the 
promoter region (Mantel, Ouaked et al. 2006). Tuovinen et al. have reported 
that natural Tregs often express two functional TCRs, which correlates to a 
higher level of FOXP3 expression (Tuovinen, Salminen et al. 2006). TCR 
signalling via two diff erent TCRs could direct thymocytes to Treg lineage 
in the human thymus. The majority of FOXP3+ thymocytes are already 
positively selected since they are detected at DP CD3high and CD4SP stages. 
However, early FOXP3 expression can be detected at the DN stage without 
TCR. There is also a minor population of pre-DP cells which express both 
FOXP3 and TCR (Nunes-Cabaco, Ribot et al. 2010). 
The same transgenic TCR can select both Treg and conventional T cells, and 
in non-transgenic settings there seems to be considerable TCR repertoire 
overlap between Treg and other T cells (Pacholczyk, Ignatowicz et al. 
2006, Wong, Obst et al. 2007). Identical TCR with the same affi  nity for the 
selecting ligand can give rise to both Treg and conventional CD4+ cells 
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(Wojciech, Ignatowicz et al. 2014). TCR signalling alone is therefore not 
enough to instruct thymocytes to commit to Treg lineage. 
4.3 Cytokines
Cytokines play an essential role in Treg development and particularly 
common γ chain cytokines induce Treg development and promote their 
survival. Mice defi cient in IL-2, IL-7 and IL-15 exhibit absence of 
regulatory T cells in the thymus and periphery (Burchill, Yang et al. 2007). 
Similarly, lack of common γ receptors in mice prevents the generation of 
Tregs (Fontenot, Rasmussen et al. 2005, Burchill, Yang et al. 2008, Tai, 
Erman et al. 2013). IL-2Rα and IL-7Rα -defi cient mice have the same 
phenotype (Bayer, Lee et al. 2008). 
In murine models Foxp3 has been reported to induce thymocytes to express 
proapoptotic protein signature and decrease the expression of Bcl-2, which 
promotes cell survival. The lethal eff ect of Foxp3 can be prevented by 
common γ chain cytokines that upregulate Bcl-2 and protect thymocytes 
from apoptosis. Foxp3+ CD25- Treg precursor cells were most prone to 
apoptosis and required common γ chain cytokines to survive and complete 
their maturation (Tai, Erman et al. 2013).
STAT5 is a downstream transcription factor that is activated by common 
γ chain receptors. The binding sites of STAT5 are Foxp3 promoter and the 
CNS2 region. A constitutively active form of STAT5 in transgenic mice 
leads to an increase in the frequency of Foxp3 Tregs and also compensates 
the absence of IL-2Rβ in Treg development (Burchill, Goetz et al. 2003, 
Burchill, Yang et al. 2007). In mice the loss of the Stat5 allele in DP 
thymocytes causes a dramatic reduction in Foxp3 CD4SP population (Yao, 
Cui et al. 2006, Burchill, Yang et al. 2007).
4.3.1 IL-2
IL-2 is a T cell growth factor that drives T cell proliferation and promotes 
the diff erentiation of CD4 Th1 and Th2 cells in the periphery (Cote-Sierra, 
Foucras et al. 2004, Liao, Lin et al. 2013). The main cellular sources 
of IL-2 are CD4 T cells and to a lesser extent CD8 T cells, NK T cells, 
activated DCs and mast cells. In the human thymus IL-2 was found both 
in the cortex and the medulla and the main producers are mature T cells 
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(Caramalho, Nunes-Silva et al. 2015). Three distinct subunits, the IL-2R α 
chain (CD25), IL-2R β chain (CD122) and common γ chain (CD132) form 
the IL-2 receptor. IL-2Rβ and common γ chain have a role in transducing 
intracellular signals. Natural Tregs express constitutively high levels of 
CD25, the α chain of IL-2 receptor, and IL-2 has been shown to be crucial 
for Treg homeostasis, expansion and function in the periphery, although 
they are unable to produce IL-2 themselves (Fontenot, Rasmussen et al. 
2005, Malek, Yu et al. 2008, Liao, Lin et al. 2013). Resting T cells express 
low level CD25 but activation by TCR or IL-2 upregulates the expression. 
Following IL-2 engagement Janus family tyrosine kinases are activated, 
leading to the phosphorylation of IL-2Rβ and the recruitment of STAT5 
proteins. In the periphery IL-2R-STAT5 signalling is essential for Treg 
suppressor function (Chinen, Kannan et al. 2016). 
In mice IL-2 induces the activation of STAT5, promotes Foxp3 and CD25 
expression, and drives Treg development in the thymus (Burchill, Yang 
et al. 2007, Cheng, Yu et al. 2013). IL-2- , IL-2Rα- and IL-2Rβ-defi cient 
mice manifest severe autoimmunity and their number of Tregs is reduced, 
whereas transgenic IL-2Rβ expression in the thymus of IL-2Rβ-defi cient 
mice restores Treg production and prevents autoimmune disease (Malek, Yu 
et al. 2002, Fontenot, Gavin et al. 2003, Hori, Nomura et al. 2003, Malek, 
Yu et al. 2008). The administration of anti-IL-2 antibodies also reduces the 
number of thymic Tregs (Bayer, Yu et al. 2005). Immature CD4+ Foxp3+ 
CD25- cells can be found in the thymus of IL2- and IL2R-defi cient mice 
but these cells are not functional and have reduced numbers of key Treg-
associated molecules that mediate suppressor function (Cheng, Yu et al. 
2013).
Based on studies in murine models a two-step-model of Treg development 
in the thymus has been proposed (Burchill, Yang et al. 2008, Lio and Hsieh 
2008). TCR signalling upregulates CD25 and increases the responsiveness 
of developing Tregs to IL-2. IL-2 induces the expression of Foxp3 and 
enhances the survival of Tregs. The expression of a Bcl2 transgene 
rescued the diff erentiation of STAT5-defi cient Treg cells indicating that 
IL-2 and STAT5 signalling play important roles in facilitating the survival 
of Tregs. In human peripheral blood IL-2 selectively induced FOXP3 
expression through STAT5 signalling pathway in CD4+ CD25+ cells but 
not in the counterparts (Zorn, Nelson et al. 2006), indicating that IL-2 
directly targets FOXP3 gene in human Tregs. Demethylation of the TSDR 
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is required for stable Treg lineage and the role of cytokines in inducing 
demethylation remains unknown. Toker et al. reported that IL-2 did not 
drive demethylation of the TSDR in CD25+ Foxp3- precursors (Toker, 
Engelbert et al. 2013). Thiault et al. demonstrated that recirculating Tregs 
inhibit Treg development in the thymus by limiting the availability of IL-2 
(Thiault, Darrigues et al. 2015).     
4.3.2 IL-7
Human regulatory T cells express the high-affi  nity α chain of IL-7R (CD127) 
at very low levels. In general, responses to IL-7 are regulated by modulating 
the receptor level. Therefore, the role of IL-7 in Treg development remains 
unclear. A common γ chain and an α subunit form the IL-7 receptor. 
Following signals through the IL-7R STAT5 is phosphorylated and activated 
by JAK kinases. In the nucleus STAT5 induces the transcription by binding 
to the FOXP3 promoter area. 
Epithelial cells  are the source of IL-7 in the thymus (Hong, Luckey et al. 
2012, Shitara, Hara et al. 2013). Early thymocyte development requires IL-7 
signalling and lack of IL-7 causes a severe defect in T cell development. The 
absence of IL-7 leads to a massive reduction of thymocytes and peripheral 
T cells in murine models (von Freeden-Jeff ry, Vieira et al. 1995, Bayer, 
Lee et al. 2008). The survival of DN cells is dictated through regulating the 
expression of Bcl-2 and the forced expression of Bcl-2 can restore thymic 
T cell development in IL-7R-defi cient mice (Maraskovsky, O’Reilly et al. 
1997). In murine models the later developmental stages are not dependent 
on IL-7 but IL-7 has been reported to promote the commitment to CD8 
cytotoxic lineage (McCaughtry, Etzensperger et al. 2012). 
At the CD4+CD8+ double positive (DP) stage murine pre-selection 
thymocytes downregulate CD127 and have been suggested to be 
unresponsive to IL-7 (Van De Wiele, Marino et al. 2004, Yu and Malek 
2006). After positive selection DP thymocytes upregulate IL7Rα and 
downregulate SOCS1 (suppressor of cytokine signalling 1) (Chong, 
Cornish et al. 2003, Yu and Malek 2006). The more mature CD4+ single 
positive (SP) thymocytes again respond to IL-7 and lack of IL-7 disturbs 
Treg cell proliferation and leads to reduced numbers of Foxp3+ cells (Tani-
ichi, Shimba et al. 2013). IL-7 can also induce Foxp3 expression in CD4 SP 
thymocytes (Wuest, Willette-Brown et al. 2008, Kim, Ligons et al. 2012). 
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In IL-7Rα- and IL-2Rβ-defi cient mice the transgenic expression of IL-7R 
led to the development of CD4+ Foxp3+ CD25- cells but did not fully 
restore Treg development (Bayer, Lee et al. 2008). 
In contrast to the murine models, in the human thymus double positive 
FOXP3+ thymocytes upregulate the expression of CD127. Exposure to 
IL-7 also led to the activation of intracellular STAT5 signalling (Nunes-
Cabaco, Caramalho et al. 2011). However, IL-7 has been considered less 
important in regulatory T cell development than other common γ chain 
cytokines (Caramalho, Nunes-Silva et al. 2015).
4.3.3 IL-15
The receptors of IL-2 and IL-15 both contain IL-2Rβ and common γ 
chain and have a distinct α chain. They also activate common signalling 
pathways but in the periphery they seem to have diff erent biological eff ects. 
IL-15 promotes the maintenance of long-lived memory phenotype cells 
(Waldmann 2006, Liao, Lin et al. 2013). IL-15-defi cient mice do not exhibit 
lethal autoimmunity disease, but in the human thymus IL-15 was identifi ed 
as an important cytokine in human Treg development. In murine T cell 
development IL-15 together with IL-7 are responsible for CD8 cytotoxic 
lineage specifi cation (McCaughtry, Etzensperger et al. 2012). IL-15Rα is 
expressed by Treg precursors although to a lesser extent compared to the 
expression of IL-2R, and mice lacking both IL-2 and IL-15 have fewer 
Tregs than IL-2Rβ-defi cient mice (Burchill, Yang et al. 2007).The lack of 
IL-15Rα did not alter the number of Tregs in mice (Soper, Kasprowicz et 
al. 2007).
IL-15 is capable of inducing STAT5 phosphorylation and the expression 
of FOXP3. Mice lacking IL-2 and IL-2β upregulated the expression of IL-
15Rα, indicating that the absence of IL-2 can be partially compensated by 
IL-15 (Vang, Yang et al. 2008). In a recent human study IL-15 was shown 
to promote Treg commitment, proliferation and survival, though to a lesser 
degree than IL-2 (Caramalho, Nunes-Cabaco et al. 2015, Caramalho, 
Nunes-Silva et al. 2015). In the human thymus mTECs, macrophages and 




There are an array of diff erent cofactors and signalling pathways that 
contribute to human Treg development. In the medullary region Hassall’s 
corpuscles produce thymic stromal lymphopoietin (TSLP) that activates 
myeloid dendritic cells (mDCs) to promote Treg development from CD4SP 
CD25neg thymocytes (Watanabe, Wang et al. 2005, Hanabuchi, Ito et al. 
2010). This induction requires the expression of CD80 and CD86 in the 
dendritic cells and IL-2. Thymic dendritic cells also produce TSLP and 
can be found in the cortex. In murine models TSLP has no direct eff ect on 
developing Tregs but it might act through other cell types as in humans 
(Vang, Yang et al. 2008). Plasmacytoid dendritic cells (pDCs) drive Treg 
diff erentiation from DP CD69high CD3high thymocytes with the stimulation of 
CD40L and IL-3 (Martin-Gayo, Sierra-Filardi et al. 2010). CD40L-CD40 
interactions maintain normal numbers of thymic Tregs and a defi ciency of 
them results in the reduction of Tregs (Williams, Tai et al. 2015). Medullary 
epithelial cells promote Treg generation by stimulating IL-2 production via 
ICOS ligand in the human thymus (Nazzal, Gradolatto et al. 2014). 
CD28 is the main costimulatory molecule in T cells and plays a signifi cant 
role in T cell activation in the periphery. Its ligands B7-1 (CD80) and B7-2 
(CD86) are also expressed in the thymus and many studies in murine models 
have reported CD28 to be necessary for Treg development in the thymus 
(Williams, Tai et al. 2015). CD28-defi cient mice have decreased frequencies 
of Tregs (Salomon, Lenschow et al. 2000) and TCR/CD28 downstream 
signalling including NFAT and AP-1 regulates Foxp3 transcription. In mice 
the expression level of CD28 is very low in double negative thymocytes 
that do not express TCRβ but it is upregulated at the DP phase (Williams, 
Hathcock et al. 2005). CD28 costimulation is required for IL-2 production 
but it also induces Foxp3 expression and upregulates CTLA-4 and GITR 
in TCR-signalled DP thymocytes in vitro (Tai, Cowan et al. 2005). Thus, 
CD28 is essential for Treg development by promoting IL-2 production 
(Jenkins, Taylor et al. 1991) but there is also an intrinsic requirement for 
CD28 costimulation. 
The role of TGF-β in thymic Treg development has been debated 
(Goldstein 2013). In the periphery it converts conventional T cells to Tregs 
and upregulates the expression of Foxp3. In murine thymus TGF-β might 
confer survival advantage to Treg precursors but does not induce Foxp3 
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expression (Ouyang, Beckett et al. 2010). In contrast, Konkel et al. have 
suggested that thymocyte apoptosis leads to the production of TGF-β, which 
in turn promotes Foxp3 induction (Konkel, Jin et al. 2014). The loss of 
TGF-β receptor I reduced the number of CD4+CD25+Foxp3+ thymocytes 
but the eff ect was only temporary. Increased production of IL-2 rescued the 
number of Tregs (Liu, Zhang et al. 2008). 
In addition to IL-2, IL-7 and IL-15, common γ chain cytokines also 
include IL-4, IL-9 and IL-21. The roles of IL-9 and IL-21 require further 
investigation. IL-9 signalling is essential for early thymocyte development 
but its role in Treg diff erentiation is unclear (De Smedt, Verhasselt et al. 
2000). 
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AIMS OF THE STUDY
I To provide an estimate of TCR diversity in the human thymus
II To study the timing of commitment to the regulatory T cell lineage
III To study the eff ects of common γ chain cytokines on regulatory T  
 cell development
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SUMMARY OF MATERIALS AND METHODS
1 CELL ISOLATION AND CULTURE
1.1 Patient samples (I-IV)
Thymic tissue was obtained from a total of 99 children (47 males, 52 
females) undergoing corrective cardiac surgery. Tissue is routinely removed 
for improved exposure during cardiac surgery. From one donor we also 
received a blood sample (I). The pediatric ethics committee of Helsinki 
University Hospital approved the study, and informed consent was obtained 
from the parents of the children. The study was performed in accordance 
with the Declaration of Helsinki.






I 4 0.5 0.1 - 0.7 1
II 13 0.3 0 - 9.3 10
III 42 0.5 0 - 10.8 20
IV 40 0.5 0 - 10.5 21
1.2 Cell isolation (I-IV)
Thymocytes were released within 6 hours of the thymectomy from the 
thymus tissue sample by mechanical homogenisation. The blood sample 
was prepared by lysing erythrocytes with brief incubation in sterile aqua.
1.3 Cell culture and apoptosis detection (III-IV)
Thymocytes were cultured in a 12-well plate with 1 millilitre human cell 
culture media (RPMI (Life Technologies, Paisley, UK), 10% heat-activated 
hAB serum (Finnish Red Cross Blood Service), 1% 100 x penicillin-
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streptomycin, 1% HEPES, 0.1% L-glutamine, 0.1% MeEtOH) overnight. 
IL-2, IL-15 and IL-7 were purchased from Immunotools and were used at 
a fi nal concentration of 25 ng/ml (IL-2) and 10 ng/ml (IL-15 and IL-7) in 
cell culture (Caramalho, Nunes-Silva et al. 2015).
Stimulation with anti-CD3 mAb was done in solution. The cells were 
incubated for 10 minutes on ice with 1 μg anti-CD3 x 106 cells, followed 
by cross-linking with 4 μg goat-antimouse IgG (Immunotools). 
Apoptosis detection was done using the apoptosis staining kit with AnnexinV 
and PI (Beckton Dickinson) according to manufacturer’s instructions. Since 
permeabilization cannot be used with apoptosis staining, Treg-associated 
marker CD25 was used instead of FOXP3. The populations of late apoptotic 
cells (AnnexinV+ PI+) and all apoptotic thymocytes (AnnexinV+PI+, 
AnnexinV+PI-, AnnexinV-PI+) were used in the analysis.
2 FLOW CYTOMETRY AND SORTING (I-IV)
2.1 Flow cytometry
The antibodies used in the experiments were direct fl uorochrome 
conjugates: CD4-APC-Cy7, CD8-PE-Cy7, CD3-PE and CD3-APC, 
CD69-FITC (Immunotools, Friesoythe, Germany), CD4-PerCP, CD8-PE-
Cy7, CD127-APC-Cy7, CD4-Biotin, Streptavidin-TexasRed, FOXP3-
APC, CD5-PerCPCy5.5, ZAP-70-PE, CD4-AlexaFluor700, CD8-FITC, 
CD8-APC, FOXP3-PE, CTLA-4-PECy5, CTLA-4-APC, CD4-APC-Cy7, 
CD25-PECy5.5, CD25-FITC (Beckton Dickinson, San Jose, CA), CD25-
PECy7, BCL-2-FITC, FOXP3-FITC (eBioscience, San Diego, CA)  and 
Ki-67-PE (Santa Cruz Biotechnology, Dallas, Texas). Following the 
surface staining the cells were fi xed, permeabilized and stained for FOXP3 
and the other intracellular molecules Ki-67, CTLA-4 and BCL-2 using 
a FOXP3 staining kit from eBioscience (San Diego, CA), according to 
manufacturer’s instructions. 
Flow cytometry was performed using the Cyan ADP instrument (Beckman 
Coulter, USA). Analysis was done with Summit 4.3 and the FlowJo 
programs (FlowJo, LLC, Oregon, USA). Fluorescence compensation 
settings were optimised using BD Bioscience CompBeads (Beckton 
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Dickinson, San Jose, CA). Since doublets in the fl ow cytometric analysis 
of the DP population may lead to erroneous assignation of FOXP3+ cells 
(Lee and Hsieh 2009), we used minimal gating in the FSC vs SSC plot. In 
addition, we analysed the data using doublet exclusion by fl ow cytometric 
height and width parameters. 
2.2 Sorting
The antibodies used in the fl ow cytometric sorting were direct fl uorochrome 
conjugates: CD3-PE, CD8-APC, CD3-FITC, CD69-APC (Immunotools, 
Friesoythe, Germany), CD25-PE, CD4-APC-Cy7, CD8-PE-Cy7 (Beckton 
Dickinson, San Jose, CA) and CD4-Pacifi c Blue (eBioscience, San Diego, 
CA). Since with permeabilization and the intracellular staining of FOXP3 
it is not possible to sort viable regulatory T cells, the surface marker CD25 
was used instead of FOXP3.
Flow cytometry and sorting were performed using the FACSAria II 
instrument. Fluorescence compensation settings were optimised using BD 
Bioscience CompBeads (Beckton Dickinson, San Jose, CA). During sorting 
we excluded doublets by using fl ow cytometric height and width parameters.
3 PCR AND SEQUENCING
3.1 RNA extraction and quantitative PCR (IV) 
Total RNA was isolated using RNeasy MiniKit according to the 
manufacturer’s instructions (Qiagen, Hilden, Germany) and fi rst-strand 
cDNA was synthesised using oligo-dT-primer (Sigma) and AMV-reverse 
transcriptase (Finnzymes, Helsinki, Finland). The mRNA level of FOXP3 
was quantifi ed using Taqman Universal Master Mix (applied Biosystems) 
and Bio-Rad iCycler (Hercules, CA).The quantitative PCR data was 
normalised against β-actin expression levels. The primer-probe sets for 
FOXP3 and β-actin were bought from Applied Biosystems. 
3.2 Methylation analysis (II-III) 
Genomic DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen, 
Hilden, Germany). Bisulfi te conversion was performed with Qiagen 
Epitect, according to the manufacturer’s instructions. The demethylation 
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status of the TSDR region was quantifi ed by real-time PCR as previously 
described with minor modifi cations (Wieczorek, Asemissen et al. 2009). 
PCR was performed with Bio-Rad iCycler (Hercules, CA).
3.3 Genomic DNA extraction and sequencing (I-II)
Frozen cell samples were either processed by Adaptive Biotechnologies 
(Seattle, USA) or genomic DNA extraction was performed in our laboratory 
according to the manufacturer’s instructions (QIAsymphony, Qiagen, 
Germany). The amount of DNA and the quality of the samples were verifi ed 
before sequencing. 
The TCR α and β CDR3 region was amplifi ed and sequenced from a 
standardised quantity of DNA. In the ImmunoSEQ assay of Adaptive 
Biotechnologies a multiplex PCR system was used to amplify the rearranged 
CDR3β and CDR3α sequences from sample DNA. This produced fragments 
of suffi  cient lenght to identify the VDJ region spanning each unique CDR3. 
Amplicons were sequenced using the Illumina platform. IMGT database 
(www.imgt.org) was used to defi ne TCRβ V, D and J, and TCRα V and 
J genes. PCR and sequencing errors were minimised using PCR bias 
correction and a modifi ed nearest-neighbour algorithm. Data was analysed 
using the ImmunoSEQ analyser toolset. 
3.4 RNA-sequencing (II)
The method of RNA sequencing was based on the Drop-seq protocol 
(Macosko, Basu et al. 2015). 10 ng of RNA was mixed with Indexing 
Oligonucleotides (Integrated DNA Technologies) and cDNA was 
constructed. cDNA samples were amplifi ed by PCR and the PCR products 
fragments were prepared using the Nextera XT (Illumina) tagmentation 
reaction. The concentration and quality of purifi ed samples were analysed 
and the libraries were sequenced using Illumina NextSeq 500 at the 
Functional Genomics Unit of the University of Helsinki. The analysis 
pipeline suggested in Macosko et al. was used. Reads were fi ltered 
to remove polyA tails of length 6 or greater and aligned to the human 
(GRCh38) genome using STAR aligner (Dobin, Davis et al. 2013) with 
default settings. Uniquely mapped reads were grouped according to the 1-8 
barcode, and gene transcripts were calculated by their Unique Molecular 
Identifi ers (UMIs) to reduce the bias emerging from the PCR amplifi cation. 
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Digital expression matrices (DGE) showed the number of transcripts per 
gene in a given sample.
4 STATISTICAL ANALYSIS
4.1 Extrapolation of total TCR diversity by rarefaction curves (I)
Rarefaction curves were constructed from the sequence data (number of 
unique TCRβ or α sequences as a function of observed cells) by generating 
a vector of TCR sequences with as many entries per sequence as observed 
in the data, randomly reordering the elements of the vector, and then 
reading the elements one by one while keeping track of the number of 
unique sequences. The resulting curves were extrapolated to n = 1.3 x 109 
cells with the software packages, preseq (Daley and Smith 2013) and DivE 
(Laydon, Melamed et al. 2014, Laydon, Bangham et al. 2015). The C++ 
package preseq computes a power-series formula that estimates how many 
times each sequence would be observed in a similar experiment of the 
same size. Using bootstrapping produces 95% confi dence intervals. The 
R package DivE fi ts 58 diff erent functions to the rarefaction curves and 
their subsamples. Then it scores each function and computes the geometric 
average of the extrapolations of the 5 best-scoring functions. Confi dence 
intervals are not produced for individual functions but the spread of the 5 
best-scoring functions can be considered as indicative of accuracy.
4.2 Extrapolation of total TCR diversity by incidence data (I)
The nonparametric estimator Chao 2 (Chao 1987) is mostly used to estimate 
species diversity in ecological unseen species studies. It considers each 
unique TCR sequence as a species and estimates the total species diversity 
based on incidence data. High overlap between species columns means that 
most of the diversity has been sampled. The R package fossil was used for 
implementing Chao 2 (Vavrek 2011).
4.3 Statistical analysis of the fl ow cytometric data (I-IV)
Statistical analysis was done with SPSS and GraphPad Prism software. The 
results are presented as arithmetic means and standard deviations. P-values 
for diff erences were calculated using Student´s two-tailed paired T-test. 
P-values <0.05 were considered signifi cant. 
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RESULTS
1 TCR diversity in the human thymus (I)
The actual diversity of the total peripheral TCR repertoire in humans 
cannot be directly measured. Previously reported assessments of TCR 
repertoire are based on sequencing T cell compartments in blood samples 
and extrapolation to actual peripheral diversity, but human intrathymic 
diversity has not been previously estimated. We provide the fi rst estimation 
of human TCR α and β diversity in the thymus and a new directly measured 
lower bound for T cell diversity. 
1.1 Sequencing of TCR genes
 
This study included four thymus samples from otherwise healthy children 
undergoing corrective cardiac surgery. Flow cytometric assessment of 
thymic populations showed a normal distribution. Thymus sample 1 was 
isolated in its entirety and contained a total of 1.3 x 109 thymocytes. Genomic 
DNA was extracted from the total amount of cells and three samples, each 
the equivalent of 12 x 106 cells, were analysed. In the thymus samples 2, 
3 and 4, 10 x 106 thymocytes were isolated and the gDNA equivalent of 
4 x 106 cells analysed. From thymus 2, two separate samples of 10 x 106 
thymocytes were extracted and analysed.
The complementarity-determining region 3 sequences of TCRβ were 
amplifi ed and sequenced from all four thymus samples and CDR3 sequences 
of TCRα/δ from thymus samples 2-4. The number of observed clonotypes 
directly yields a lower bound of T cell diversity. Since some T cells express 
α chains utilising Vδ or Jδ gene segments (Chien et al. 1987, Satyanarayana 
et al. 1988) it was not possible to reliably separate TCRα and TCRδ loci. 
A small part of the sequences was therefore likely to be derived from γδ T 
cells. 
From sample 1 we obtained an average of 47.4 x 106 TCRβ reads per replicate 
and 17.1 x 106 reads from thymuses 2-4 and approximately 80% of the 
sequences were productive (I, Table I). The number of unique productive 
TCRβ sequences found ranged from 1.5 x 106 in thymus 4 to 10.3 x 106 
in thymus 1 when all three replicates were combined, the highest TCRβ 
diversity so far directly measured. From thymus samples 2-4 we obtained 
58
an average of 34.9 x 106 TCRα reads. Only 32% of them were productive; 
this is most likely due to the lack of allelic exclusion in the TCRα locus (I, 
Table II). From the two combined replicates of thymus 2 we measured 3.7 
x 106 unique productive sequences which is the highest directly measured 
TCRα diversity to date. In addition, we received a blood sample from the 
donor of thymus 1. Sequencing of 3.4 x 106 total TCRβ reads produced 86 
000 unique productive sequences and 4000 of them were shared with the 
thymus repertoire.
1.2 Estimation of total TCRβ diversity
Since the sample size in sequencing is limited we used three computational 
estimators to extrapolate the total diversity in the entire thymus. The 
replicates of thymus 1 shared only a small fraction of the repertoire, 
indicating signifi cantly larger total diversity. Estimators preseq and DivE 
were based on measuring the saturation of rarefaction curves and Chao2 on 
the size of the overlap between samples. Rarefaction curves measure the 
number of observed unique TCRβ sequences as a function of the number 
of sequenced cells and they saturate when the complete diversity has been 
sampled. Estimator preseq (Daley and Smith 2013) produced 73.1 x 106 
unique TCRβ sequences in the thymus 1, with 95% confi dence intervals 
of 43.3 - 129.9 x 106, and between 13.9 x 106 and 37.6 x 106  in thymus 
samples 2-4 (Table II). 
DivE is also based on rarefaction curves but fi ts a large number of functions 
to the curves, scores each with 4 criteria and uses the geometric mean of 
the fi ve best models as the fi nal estimate (Laydon, Melamed et al. 2014). In 
the thymus 1 DivE extrapolated 42.5 x 106 unique TCRβ sequences and 9.2 
- 10.5 x 106 unique sequences in samples 2-4. Chao2 is based on incidence 
data and it estimated a total diversity of 46.4 x 106 unique sequences in the 
thymus 1 and 30.0 x 106, 10.0 x 106 and 9.6 x 106 sequences in thymuses 
2-4 (Table II).
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Table II. TCR diversity estimates (x106)
  
Sample Preseq DivE Chao2
TCRβ
1 73.1 42.5 46.4
2 37.6 10.5 30.0
3 18.7 9.6 10.1
4 13.9 9.2 9.6
TCRα
2 83.4 28.8 103.0
3 18.6 16.9
4 37.7 22.7 19.5
1.3 Estimation of total TCRα diversity
 
Estimates of the TCRα repertoire in thymuses 2-4 yielded consistently 
higher numbers of unique sequences than corresponding TCRβ diversity. 
Preseq produced 83.4 x 106 sequences in thymus 2 and 37.7 x 106 in thymus 
4 but failed for thymus 3. DivE extrapolated to 28.8 x 106, 18.6 x 106 and 
22.7 x 106 unique TCRα sequences in thymuses 2-4 and the estimates based 
on Chao2 were 103 x 106, 16.9 x 106 and 19.5 x 106 TCRα sequences in 
thymuses 2-4, respectively (Table II).
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2 TCR repertoire in the regulatory T cells in the human thymus (II)
2.1 Sequencing of TCR genes in the sorted thymic populations
It has been previously shown that DP regulatory T cells contribute to the 
CD4SP Treg pool in the human thymus (Nunes-Cabaco, Caramalho et al. 
2011). To analyse the Treg developmental pathway we sorted CD25+ DP 
and CD25+ CD4SP subsets as well as their CD25- counterparts from 5 
pediatric thymus samples (samples A-E). The donors were otherwise healthy 
children undergoing corrective cardiac surgery. To avoid analysing doublets 
as DP cells a strict gating strategy was used. Since with permeabilization 
and the intracellular staining of FOXP3 it is not possible to sort viable 
regulatory T cells, the surface marker CD25 was used instead of FOXP3. 
The mean frequency of CD25+ cells was 0.7% (range 0.5-0.9%) in the DP 
population and 14.2% (range 11.9-15.7%) in the CD4SP population. 
Genomic DNA was extracted from the sorted populations. The 
complementarity-determining region 3 (CDR3) sequences of TCRβ were 
then amplifi ed and sequenced. The obtained reads depended on the size of 
the cell subset in the thymus. 70-80% of the sequences were productive. 
The number of unique productive TCRβ sequences found ranged from 600 
to 50 000. We sorted thymus samples A and B to six diff erent populations: 
CD4SP, CD8SP, DP CD3high, DP CD3low, DP CD25+ and CD4+ CD25+ cells 
and the samples C, D and E to four populations: DP CD25+, DP CD25-, 
CD4SP CD25+ and CD4SP CD25-. In samples A and B we combined the 
data in the populations DP CD3high and DP CD3low to form a DP CD25- 
subset. In these combined cell subsets the CD25+ cells were not excluded 
in the sorting.  
Consistent with the previously reported shortening of CDR3 during thymic 
selection, the CDR3 length was shorter in the productive rearrangements 
than in the nonproductive rearrangements in all populations. At the DP 
stage the mean CDR3 was longest 45.6bp and the length shortened during 
development. The shortest lengths were detected in DP CD25+ (mean 
43.4bp) and CD4 CD25+ (mean 43.7bp) cells. 
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2.2 DP CD25+ and CD4 CD25+ thymocytes share nucleotide 
and amino acid sequences
To track the developmental pathway of the regulatory T cells at the DP 
stage we compared the repertoire between DP CD25+ and other thymic 
populations by calculating the Jaccard index obtained by dividing the 
number of shared sequences by the combined size of the samples. We 
compared the overlap between the regulatory populations, between DP 
CD25+ and CD4SP populations and between DP CD25+ and the total DP 
population. Comparing the common unique and total number of nucleotide 
sequences showed that DP CD25+ and CD4 CD25+ populations were 
clearly closer to each other than any other population and the average 
Jaccard indexes 0.0022 (unique common sequences) and 0.0079 (total 
common sequences) were higher than between other populations. Thymic 
CD4SP population had unexpectedly low total reads which is one source 
of error in the analysis. In the nonproductive repertoire the regulatory 
populations were also closer to each other than any other populations.
In the repertoire of amino acid sequences the results were similar to 
nucleotide sequence analysis. In most of the samples the Jaccard index 
between DP CD25+ and CD4 CD25+ populations was higher than in the 
other two combinations and the average Jaccard indexes were 0.0049 
(unique amino acid sequences) and 0.0130 (total amino acid sequences). 
This data supports the conclusion that especially at the nucleotide sequence 
level, DP CD25+ thymocytes share a similar TCR repertoire with the CD4 
CD25+ population indicating that they are part of the common clonal and 
developmental pathway. 
In samples A and B we compared the overlap between DP CD25+ 
thymocytes and DP CD3high, DP CD3low, CD4SP and CD8SP populations. In 
both nucleotide and amino acid sequence levels the highest Jaccard index 
was calculated with a DP CD3high subset. It has been previously shown that 
most Tregs express CD3 and are positively selected (Tuovinen, Pekkarinen 
et al. 2008, Lehtoviita, Rossi et al. 2009). The overlap with other thymic 
populations was quite small.
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2.3 Methylation analysis of the DP and CD4SP CD25+ 
populations
We have previously shown that both DP and CD4SP FOXP3+ thymocytes 
give equal expression of FOXP3 on a single cell level measured with mean 
fl uorescence intensity (Tuovinen, Pekkarinen et al. 2008). However, the 
epigenetic status of the Treg-specifi c demethylated region (TSDR) has also 
been shown to be essential in stabilising Treg phenotype (Toker, Engelbert 
et al. 2013). To test the demethylation status of the developing Tregs at the 
DP and CD4SP stage in the human thymus, we sorted four thymus samples 
(thymus samples F-I) to DP CD25+ and CD4SP CD25+ populations and 
isolated the genomic DNA. A real-time PCR method quantifi ed the relative 
proportion of methylated and demethylated TSDR DNA using methylation-
dependent amplifi cation primers (Wieczorek, Asemissen et al. 2009). The 
mean delta Ct value (ΔCt = Ct (demethylated DNA) – Ct (methylated DNA)) 
was 6.2 ± 0.2 in the DP CD25- and 6.0 ± 0.1 in the CD4 CD25- population. 
In both DP and CD4 CD25+ cells the mean ΔCt value was signifi cantly 
lower (0.8 ± 0.2 and 0.8 ± 0.6, p<0.001, n=4). There was no diff erence 
between the DP and CD4 CD25+ populations in their demethylation status. 
Thus, a stable Treg phenotype can be detected already at the DP stage. 
2.4 Diff erential gene expression analysis of DP and CD4SP Tregs
To further characterise the human regulatory populations in the thymus we 
used RNA sequencing. We again sorted DP CD25+ and CD4SP CD25+ 
thymocytes from 4 pediatric thymus samples (thymus samples J-M) and 
analysed gene expression changes between these populations using the 
edgeR Bioconductor package. In the analysis we found no statistically 
signifi cantly expressed genes between DP CD25+ and CD4SP CD25+ cells.
3 The role of cytokines in regulatory T cell development (III-IV)
Regulatory T cell development has been extensively studied in murine 
models and common γ chain cytokines have been identifi ed as essential 
(Burchill, Yang et al. 2007, Burchill, Yang et al. 2008). A two-step-model 
suggests that TCR signalling induces the expression of CD25 and allows 
the cytokines to promote Treg development at the CD4 single positive stage 
(Burchill, Yang et al. 2008, Lio and Hsieh 2008). However, human studies 
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favour an earlier emergence of Tregs at the CD4+CD8+ double positive 
stage. We have studied the role of cytokines IL-2, IL-7 and IL-15 at the DP 
phase in the human thymus. 
3.1 Interleukin-2 (IV)
3.1.1 IL-2 selectively promotes the development of the most 
mature DP cells
IL-2 has been suggested to be the main cytokine enhancing Treg development 
at the CD4SP stage (Caramalho, Nunes-Cabaco et al. 2015) but FOXP3 
upregulation has also been reported at the DP stage (Nunes-Cabaco, 
Caramalho et al. 2011). Since commitment to the regulatory lineage in the 
human thymus already starts at the DP stage, we analysed in detail the 
role of IL-2 in the development of FOXP3+ DP cells and subdivided DP 
thymocytes into three maturation stages based on CD3 expression levels. 
At the earliest stage thymocytes lack the CD3 molecule on their surface 
but start to express it at the CD3low phase. The transition to the CD4SP 
stage takes place after the most mature DP CD3high stage. The expression 
of the high-affi  nity IL-2 receptor CD25 in the FOXP3+ thymocytes varied 
between the diff erent developmental stages. It was very low at the CD3neg 
stage, but then increased to 26.0% ± 13.9% at the CD3low and 39.8% ± 
11.2% at the CD3high stage (IV, Figure 3A).
Thymocytes were cultured overnight with or without stimulation with IL-
2. In general, IL-2 produced a signifi cant increase in the FOXP3 mRNA 
level in the thymocyte population. The relative amount of FOXP3 mRNA 
was measured with quantitative PCR, using β-actin to normalise the data. 
In the fl ow cytometric analysis IL-2 increased the frequency of FOXP3+ 
cells from 0.7 % ± 0.5% to 1.0% ± 0.6% (p<0.01, n=6) within the DP 
population and also the FOXP3 content on a single cell level, as measured 
by mean fl uorescence intensity (MFI) (IV, Figure 1). To analyse this in 
more detail we subdivided DP thymocytes into three maturation stages. 
Based on the expression of CD25, IL-2 has the potential to infl uence the 
developing thymocytes from at least the DP CD3low stage onwards. The 
highest FOXP3+ frequency was detected in the positively selected DP 
CD3high population. IL-2 did not have an eff ect on FOXP3 expression at the 
early DP stages but increased both FOXP3+ frequency from 2.4% ± 1.4% 
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to 3.5% ± 2.0% (p<0.05) and FOXP3 MFI from 36.1 ± 21.1 to 53.1 ± 24.5 
(p<0.01) at the most mature CD3high stage (IV, Figure 3B).
IL-2 also promoted the expression of Treg-associated markers CTLA-4 
(cytotoxic T-lymphocyte-associated molecule-4) and CD25. Within the 
FOXP3+ DP population the expression of intracellular CTLA-4 increased 
from 9.3% ± 1.6% to 13.2% ± 2.6% (p<0.01, n=8) and the CTLA-4 MFI 
from 156.6 ± 16.3 to 182.0 ± 22.4 (p<0.05). The biggest increase was 
detected at the DP CD3high stage (IV, Figure 3C). A minor increase in the 
frequency of CTLA-4 expressing cells was seen already at the CD3low stage 
but not in CTLA-4 MFI. Likewise, the frequency of CD25+ cells and CD25 
MFI increased in the DP population after IL-2 stimulation (IV, Figure 2C). 
Thus, exposure to IL-2 at the DP stage both upregulates the expression 
of FOXP3 and promotes Treg associated markers and Treg phenotype. 
Together, these results suggest that IL-2 both upregulates the expression of 
FOXP3 and promotes Treg associated markers and Treg phenotype at the 
DP stage but only at the most mature DP CD3high stage. 
3.1.2 Interleukin-2 enhances DP FOXP3+ cell survival
To study the eff ects of IL-2 on cell survival, we used Annexin V / propidium 
iodide staining for apoptosis detection and measured the expression of 
anti-apoptotic protein BCL-2 (B-Cell Lymphoma 2). The surface marker 
CD25 was used instead of FOXP3, since permeabilization of the cells is not 
compatible with the detection of apoptotic cells. The overnight culture with 
IL-2 decreased the frequency of Annexin V+PI+ late apoptotic cells within 
the CD25+ DP population from 50.5% ± 20.4% to 33.1% ± 18.5% (n=11, 
p<0.001) (IV, Figure 5A-B). In their counterparts (CD25- DP subset) very 
few apoptotic cells were observed, and IL-2 had no detectable eff ect. 
BCL-2 expression was sharply downregulated during the transition from 
DN to DP stage, but in the DP FOXP3+ subset the frequency of BCL-2+ 
cells was signifi cantly higher than in their FOXP3- counterparts, with an 
increasing trend in subsequent maturation stages. There was also an inverse 
correlation with cell proliferation, with most of the DP FOXP3+ cells 
expressing either BCL-2 or Ki-67 but not both (IV, Figure 5D). Overnight 
culture with added IL-2 induced a clear increase both in the expression of 
BCL-2 and BCL-2 MFI in the DP FOXP3+ population (IV, Figure 5E-F). 
Again, the eff ects were most prominent in the most mature FOXP3+ DP 
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CD3high stage, in which IL-2 increased BCL-2 frequency from 57.5% ± 
25.0% to 64.0% ± 26.1% (p<0.05, n=10) and BCL-2 MFI from 115.2 ± 
45.8 to 166.9 ± 61.7 (p<0.01) (IV, Figure 7A). At the CD3low stage IL-2 
had a minor increasing eff ect on BCL-2 MFI. Taken together, this data 
shows that DP CD25+ thymocytes were highly susceptible to apoptosis but 
IL-2 promoted their survival and induced anti-apoptotic BCL-2 at the most 
mature DP CD3high stage. 
It has been previously reported that IL-2 increases proliferation of FOXP3+ 
thymocytes at day 4 of culture (Caramalho, Nunes-Silva et al. 2015). We 
also measured the expression of the cell cycle marker Ki-67 after overnight 
culture. DP FOXP3+ cells were rapidly dividing, with 37.8% ± 27.2% 
expressing Ki-67, but IL-2 had no signifi cant eff ect on their proliferation in 
any of the FOXP3+ DP subsets. DP cells are also subject to TCR-mediated 
selection, and IL-2 might modulate TCR-signalling and thus promote Treg 
maturation. To analyse the impact of IL-2 on TCR signalling we co-cultured 
the cells with anti-CD3 mAb and IL-2. This increased the frequency of 
FOXP3+ cells in the DP population from 0.3% ± 0.3%  to 0.8% ± 0.8% 
(n=6, p<0.05) but this did not diff er signifi cantly from the eff ects of IL-2 
stimulation alone (IV, Figure 4B).
Figure 7. The eff ects of common γ chain cytokines on the expression 
of BCL-2 in the DP FOXP3+ thymocytes. The mean (± SD) frequency 
of BCL-2 + cells in the DP FOXP3+ population with and without each 
cytokine in overnight culture. * P < 0.05, ** P < 0.01
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3.2 Interleukin-7 (III-IV)
3.2.1 The expression of IL7R-α during thymic development
Although human peripheral regulatory T cells are defi ned by the low 
expression of CD127, it has been shown that CD127 is upregulated in 
FOXP3+ thymocytes at the DP stage (Nunes-Cabaco, Caramalho et al. 
2011). We analysed CD127 expression in FOXP3+ and FOXP3- thymocyte 
populations at the diff erent DP stages. In the FOXP3+ population, the 
highest expression of CD127, measured as mean fl uorescence intensity 
(MFI), was detected in the DN population. At the DP stage CD127 MFI 
had a declining trend from CD3neg to CD3high stage with the sharpest drop 
occurring in the transition to SP stage (III, Figure 1). In contrast, in the 
FOXP3- population CD127 MFI peaked at the DP CD3high stage. The 
expression patterns of FOXP3+ and FOXP3- signifi cantly diff ered from 
each other. The culture of DP FOXP3+ thymocytes with IL-7 led to CD127 
downregulation by 40.0% ± 25.0% (p<0.05), indicating that DP Tregs are 
capable of responding to IL-7.
3.2.2 IL-7 promotes the development of regulatory T cells at the 
DP stage
To study the eff ects of IL-7 at the DP stage, we cultured human thymocytes 
overnight with and without IL-7. The frequency of DP FOXP3+ cells 
increased from 0.2% + 0.1% to 0.4 % ± 0.2% (p<0.008, n=9) with IL-7 
exposure (III, Figure 2C). The single-cell level expression of FOXP3 
measured with MFI in the DP FOXP3+ population did not signifi cantly 
diff er from the CD4SP stage. FOXP3 MFI increased from 27.3 ± 4.3 to 
35.2 ± 8.5 (p<0.02) at the DP stage. 
A similar increase was detected in the Treg-associated markers cytotoxic 
T-lymphocyte-associated molecule-4 (CTLA-4) and CD25 (IL-2R). Both 
the frequency of CD25+ cells in the DP population and the expression of 
intracellular CTLA-4 increased in the DP FOXP3+ cells (III, Figures 3 and 
5). IL-7 also induced an increase of CTLA-4 MFI within DP FOXP3 cells, 
indicating that it promotes Treg-associated phenotype. 
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3.2.3 IL-7 prevents apoptosis of regulatory T cells
To study the mechanisms that IL-7 uses to promote Treg development, 
we measured the expression of BCL-2 and the frequency of apoptotic 
cells with Annexin V and propidium iodide staining, defi ning apoptotic 
cells as including all but Annexin V/propidium iodide double-negative 
cells. DP CD25+ cells are highly susceptible to apoptosis, with 57.6% 
± 16.9% apoptotic cells after overnight culture. IL-7 signifi cantly 
decreased the frequency of apoptotic cells to 42.1% ± 13.5% (p<0.03, 
n=13) (III, Figure 6). In the DP CD25- subset IL-7 induced a minor 
decrease. The frequency of BCL-2 in the DP FOXP3+ population after 
overnight culture with IL-7 increased from 32.0% ± 19.0% to 50.9% ± 
30.4% (p<0.05, n=10) and BCL-2 MFI from 172.1 ± 60.2 to 242.9 ± 17.4 
(p<0.01) (IV, Figure 6F-G). Analysis of the diff erent CD3 stages showed 
that the major eff ect of IL-7 was detected in the DP CD3high FOXP3+ 
subset but it also increased the BCL-2 frequency at the CD3low stage. 
We then tested whether IL-7 aff ects TCR signalling, proliferation or 
methylation status of DP FOXP3 cells. We analysed whether preincubation 
with IL-7 changes the response of FOXP3+ DP cells to stimulation by anti-
CD3 mAb. CD3 mAb stimulation alone induced an increase in CD69 MFI, 
a marker of positive selection, in DP thymocytes. Preincubation with IL-7 
before stimulation via CD3 increased the frequency of FOXP3+ cells but 
these levels were not higher than those measured in cells incubated with 
IL-7 alone (III, Figure 4A). Similar to IL-2, IL-7 did not have an eff ect on 
TCR signalling. IL-7 is a growth factor and we measured the expression of 
the cell cycle marker Ki-67 in the DP FOXP3+ thymocytes. No increase 
was detected in the proliferation of DP FOXP3+ cells (III, Figure 4B). 
Epigenetic changes in the Treg-specifi c demethylated region have been 
shown to be important in stabilising the Treg phenotype (Toker, Engelbert 
et al. 2013). To study whether IL-7 induces TSDR demethylation we used 
a real time quantitative PCR method previously described by Wierczorek 
et al. to measure the relative proportion of methylated and demethylated 
TSDR DNA (Wieczorek, Asemissen et al. 2009). IL-7 did not aff ect the 
methylation status but it is possible that subtle changes could have been 
missed since we used unsorted thymocytes. 
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3.2.4 IL-7 also increases FOXP3 expression in CD4 cells 
The expression of CD127 in the CD4SP FOXP3+ thymocytes is low but 
we tested whether IL-7 has any eff ect on them. Surprisingly, stimulation 
with IL-7 resulted in a signifi cant increase of FOXP3+ cells and FOXP3 
MFI (III, Figure 7A-B). Similar eff ects were detected in the expression of 
intracellular CTLA-4 and CD25 (III, Figure 7D-F). CD4SP CD25+ cells 
were much less prone to apoptosis than DP cells. Only 10.2% ± 8.5% of 
them were apoptotic after overnight culture and adding IL-7 decreased the 
frequency to 3.2 % ± 1.4% (p<0.02). Thus the eff ects of IL-7 were very 
similar in the DP and SP populations, despite the low CD127 expression in 
CD4SP FOXP3 cells. 
3.3 Interleukin-15 (IV)
Similar to IL-2 and IL-7, overnight culture with exogenous IL-15 
increased the frequency of DP FOXP3+ cells from 0.4% ± 0.3% to 0.8% 
± 0.6%  (p<0.05, n=8) and FOXP3 MFI from 22.2 ± 4.1 to 27.4 ± 4.7 
(p<0.01) (IV, Figure 6A-B). The most prominent increase was detected at 
the DP CD3high stage and no signifi cant increase of FOXP3 was detected 
at the earlier DP stages. IL-15 also induced a decrease of late apoptotic 
Annexin V+ PI+ cells (IV, Figure 6C). The expression of BCL-2 increased, 
as well, but to a lesser degree than observed with IL-2 and IL-7, and there 
was no signifi cant eff ect on BCL-2 MFI. In contrast to the other cytokines 
the increase in BCL-2 frequency was observed in the FOXP3+ DP CD3low 
cells and not in the CD3high cells (IV, Figure 7).
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DISCUSSION
1 TCR diversity in the human thymus
A diverse TCR repertoire is essential for the immune system to recognise 
foreign antigens and defend the body against the universe of potential 
pathogens. This diversity is generated by somatic recombination of the 
TCR α and β gene segments in the thymus. Previous reports have estimated 
the total TCR diversity in the peripheral mature repertoire, identifying 1-3 x 
106 unique TCRβ and 0.5 x 106 unique TCRα sequences. However, human 
intrathymic TCR repertoire diversity has not been previously studied. 
High-throughput sequencing has enabled the identifi cation of large 
numbers of TCR sequences from a single individual but total TCR 
diversity cannot be directly measured. In the peripheral blood only a small 
fraction of the lymphoid compartment can be sequenced in one sample. 
In pediatric thymus samples from children undergoing cardiac surgery the 
whole repertoire could be sampled and sequenced at least in theory. The 
limitations of the sequencing technology obliged to us to use mathematical 
estimators; we used three of these, preseq, DivE and Chao2, all with 
potential confounding factors. DivE fi ts 58 functions to the rarefaction 
curves, scores each function and selects the 5 best-scoring functions. The 
criteria for scoring are empirical and nonstandard. Low curvature in the 
rarefaction curves indicates too low sampled diversity and the results may 
be incorrect. Too low overlap between samples disturbs the estimation 
with Chao 2. However, the estimates from our thymus samples resulted in 
generally convergent outcomes. 
The high-throughput sequencing of the thymus samples directly measured 
10 million unique in-frame TCRβ sequences and 4 million TCRα sequences, 
the highest directly observed diversity so far for either chain. Computational 
estimators extrapolated the diversity to 40-70 x 106 unique TCRβ sequences 
and 60-100 x 106 TCRα sequences. Since each β chain can pair with at least 
25 diff erent α chains in the periphery (Arstila, Casrouge et al. 1999), actual 
TCRαβ diversity is signifi cantly higher. In the thymus this pairing ratio is 
unlikely to be as high as in the periphery since the extensive thymocyte 
elimination complicates calculating the number of αβ heterodimers in the 
thymus.
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Previous studies have reported peripheral TCRα diversity to be lower than 
in the β repertoire but in the thymus our data indicates the opposite. Our 
results showed thymic TCRα diversity to be 2-fold higher than TCRβ, which 
can be explained by the thymic maturation pathway and the mechanisms 
of the TCRα rearrangement and pairing with the β chain. The TCRβ 
chain rearrangement takes place at the double negative stage and the cells 
proliferate before the rearrangement of the V and J regions in the α chain 
locus. Therefore, thymocytes with the same β chain can pair with large 
numbers of diff erent α chains. TCRα chain locus can go through multiple 
rearrangements whereas the recombination in the β locus occurs only 
once. Maximising the production of in-frame thymocytes is essential since 
positive and negative selection enormously limit the diversity. However, 
TCRα diversity probably contracts during positive and negative selection 
leading to lower peripheral α chain diversity. 
Qian Qi et al. have previously used high-throughput sequencing and Chao2 
estimator to estimate 100 million unique TCRβ sequences in naïve CD4 and 
CD8 T cell repertoires of young adults (Qi, Liu et al. 2014). Compared to this 
report, our results of 40-70 x 106 thymic β chains from the human thymus 
are smaller and the negative selection reduces the diversity even more. This 
is not surprising since selections and thymocyte egress constantly shape the 
transient repertoire. The extensive clonal deletion of thymocytes is apparent 
in the loss of TCRα diversity, when thymus and periphery are compared. 
Thymic diversity and clonal composition is continuously changing and our 
estimate describes the situation at one given time point. Dynamic thymic 
repertoire produces the clones for the peripheral T cell compartment. 
Comparing the repertoire in the thymus and blood sample from donor 1 
showed that 4.7% of the peripheral β sequences were shared between them. 
This indicates some continuity between thymus and peripheral repertoire 
but recirculation may also contribute to the overlap. 
We provide the highest directly measured diversity to date and the fi rst 
estimate of the size of the human thymic TCR repertoire with 40-70 x 106 
unique TCRβ sequences and 60-100 x 106 TCRα sequences. The thymic 
repertoire is thus extremely diverse, but based on the minor overlap 
between thymus and peripheral blood it is also likely to be transient and 
consists of variable clonal compositions with diff erent clones produced at 
diff erent times. The fi rst steps have been made in measuring TCR diversity 
in diff erent T cell compartments. In the future TCR sequencing provides 
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possibilities for characterising more deeply diff erent T cell populations 
during thymic development. 
Single-cell technologies have revealed the cellular heterogeneity of the 
immune cell populations (Islam, Zeisel et al. 2014, Proserpio and Lonnberg 
2016) and identifi ed unknown rare T cell subpopulations (Kakaradov, 
Arsenio et al. 2017). The analysis of rare cell types and TCR specifi cities 
of single thymocytes is essential for studying developmental pathways and 
selections in the thymus. In the future single cell studies are required to 
understand the complex T cell biology in autoimmunity and cancer.
2 Regulatory T cell development in the human thymus
Somatic recombination produces a diverse thymic TCR repertoire including 
also the thymocytes instructed to develop into regulatory T cells. Tregs and 
conventional T cells are suggested to arise as separate cell lineages and 
according to a two-step model TCR signalling increases the responsiveness 
of developing Tregs to IL-2 that induces the expression of Foxp3. The 
timing of the regulatory T cell commitment in the thymus is a matter of 
debate and the diff erences between human and mice are notable. The fi rst 
FOXP3+ cells can be found already at the double negative stage (Tuovinen, 
Kekalainen et al. 2008, Liu, Li et al. 2014). In murine models Tregs are 
suggested to arise from Foxp3- precursors at the CD4 SP stage (Fontenot, 
Gavin et al. 2003, Fontenot, Dooley et al. 2005) with no direct link with DP 
Foxp3+ population in the thymic cortex. However, Treg cell commitment 
can occur in the cortex and the data from human studies favours this earlier 
commitment at the DP phase (Nunes-Cabaco, Caramalho et al. 2011). 
The main regulatory population comprises mature CD4 single positive 
thymocytes but the population is also clearly detected at the DP stage. Both 
the thymic medulla and cortex can support Treg development (Liston, Nutsch 
et al. 2008). DP FOXP3+ thymocytes express Treg-associated molecules, 
including CD25, CD39, GITR and CTLA-4 and exhibit suppressive 
capacity (Cupedo, Nagasawa et al. 2005, Darrasse-Jeze, Marodon et al. 
2005, Liotta, Cosmi et al. 2005, Nunes-Cabaco, Caramalho et al. 2011). 
The majority of them are functionally mature and positively selected since 
they express high levels of CD3 and CD69 (Tuovinen, Pekkarinen et al. 
2008, Lehtoviita, Rossi et al. 2009). Furthermore, linear regression models 
reported by Nunes-Cabaco et al. indicate that the FOXP3+ DP population 
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is the major contributor to the FOXP3+ CD4 SP subset (Nunes-Cabaco, 
Caramalho et al. 2011). 
The TCR repertoire of Tregs has been reported to be specifi c to self-antigens 
(Hsieh, Zheng et al. 2006, Kim, Rasmussen et al. 2007, DiPaolo and 
Shevach 2009, Lee, Bautista et al. 2012) and the selection to Treg lineage 
requires intermediate-to-high TCR affi  nity to self-antigens (Caton, Kropf 
et al. 2014). Earlier studies have suggested partial overlapping between 
human peripheral Tregs and CD4 CD25- T cells (Fazilleau, Bachelez et 
al. 2007) but recent data indicates that regulatory and conventional T cells 
are completely distinct and non-overlapping (Golding, Darko et al. 2017). 
In murine thymus 6% of TCR sequences were shared between developing 
Tregs and conventional T cells (Wolf, Emerson et al. 2016). It was argued 
that since these cells share identical nucleotide code, they are derived from 
a common progenitor. 
To track the developmental pathway of human regulatory T cells in the 
thymus we sorted DP CD25+ and CD4+ CD25+ thymocytes to compare 
the overlap between their TCR repertoires. CD25 is not a defi nitive marker 
for Tregs since it can be upregulated by conventional T cells. However, it 
is most commonly used for the purifi cation of Tregs. Fazilleau et al. have 
detected a high level of FOXP3 in human peripheral CD4 CD25high cells 
(Fazilleau, Bachelez et al. 2007) and Tuovinen et al. have shown that high 
expression of CD25 is associated with FOXP3 in DP and CD4SP thymocytes 
(Tuovinen, Pekkarinen et al. 2008). To calculate the overlap between DP 
and CD4SP Tregs we used Jaccard index and the results showed that these 
populations were closest to each other on the nucleotide sequence level 
compared to other cell subsets. DP Tregs seem to be part of the common 
developmental pathway with CD4SP Tregs in the human thymus. 
Demethylated TSDR is a key marker of natural regulatory T cells and it can 
be used to quantify Tregs in human peripheral blood instead of only FOXP3 
expression. TSDR is a CpG-rich intronic enhancer region that regulates 
and maintains stable FOXP3 expression. Although conventional T cells can 
transiently induce FOXP3 expression, it is not suffi  cient to establish natural 
Treg phenotype since it does not induce all the Treg signature genes or lead 
to acquisition of suppressor function. Data from murine models has shown 
that the demethylation of TSDR is essential for thymic Treg development 
(Ohkura, Hamaguchi et al. 2012, Kitagawa, Ohkura et al. 2015), but the 
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demethylation pattern of TSDR during thymic development is unclear and 
the pathways leading to demethylation of TSDR are only partially known 
in humans. In murine thymus several Treg-associated gene regions such as 
CD25, CTLA-4, Eos and GITR have been recognised to be demethylated 
in regulatory lineage (Ohkura, Hamaguchi et al. 2012). The demethylation 
of TSDR was initiated during the early stages of thymic development and 
it could occur independently of FoxP3 expression (Ohkura, Hamaguchi 
et al. 2012). On the other hand, Toker et al. have shown that active 
demethylation of TSDR occurs in parallel with the induction of Treg-type 
gene expression and was completed as Tregs emigrated from the thymus 
(Toker, Engelbert et al. 2013). We compared the methylation status of the 
regulatory CD25+ populations between DP and CD4SP stages in the human 
thymus. Both Treg populations had a demethylated TSDR compared to 
their CD25- counterparts and no diff erence was seen between them. This 
data suggests that a stable Treg phenotype can be detected already at the DP 
stage supporting the previously reported data from the human studies. The 
commitment to Treg lineage can occur already at the double positive stage 
in the human thymus. 
3 Cytokines dictate regulatory T cell development at the double 
positive stage
The factors inducing FOXP3 and enhancing commitment to the Treg lineage 
are only partially known in the human thymus. The development of the 
regulatory phenotype could also precede Foxp3 induction that stabilises the 
phenotype (Gavin, Rasmussen et al. 2007, Lin, Haribhai et al. 2007).The 
role of TCR-signals is essential and the selection to Treg lineage requires 
intermediate-to-high TCR affi  nity to self-antigens. Based on the data from 
murine models the two-step-model has been suggested. According to it 
TCR signalling upregulates IL-2R and increases the responsiveness of 
developing Tregs to IL-2 and other common γ chain cytokines that provide 
the second signal and induce the expression of Foxp3. The data from 
human studies supports earlier Treg commitment than in mice and thus I 
have concentrated in this thesis on the eff ects of cytokines IL-2, IL-7 and 
IL-15 at the double positive stage. 
FOXP3+ thymocytes are fi rst observed already at the CD4-CD8- double 
negative population stage (Liu, Li et al. 2014), where they lack TCR. 
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We have subdivided the DP phase into three stages based on the CD3 
surface expression to study the eff ects of diff erent cytokines. At the early 
DP stage thymocytes lack CD3 but start to express it at the DP CD3low 
stage. A functional TCR is fi rst expressed at the DP CD3low stage and 
afterwards thymocytes are subjected to positive selection. At the most 
mature DP stage high expression of CD3 is detected. Positively selected 
FOXP3+ thymocytes are clearly found at the DP stage and they express 
Treg-associated markers. At the DP CD3high stage their FOXP3 expression 
measured with MFI is as high as in the CD4SP Tregs (Josefowicz, Lu et 
al. 2012). In this thesis I have studied at which stage the cytokines have an 
impact on Treg development. 
Common γ chain cytokines are available for developing regulatory T cells 
in both thymic cortex and medulla. IL-7 has an essential role already in 
early T cell development and is secreted by thymic epithelial cells in the 
cortex (Mazzucchelli and Durum 2007, Tai, Erman et al. 2013). Caramalho 
et al. have also reported that IL-2 is expressed in both cortex and medulla 
and is thus available for developing T cells at the DP stage (Caramalho, 
Nunes-Silva et al. 2015). IL-15 is produced by macrophages and B cells in 
the thymus. 
Regulatory T cells express high levels of CD25 and IL-2 is essential for the 
maintenance of the Treg population in the periphery. IL-2 signalling leads 
to phosphorylation of the transcription factors STAT3 and STAT5, which 
directly bind to a specifi c site in the fi rst intron of the FOXP3 gene and 
initiate its expression (Zorn, Nelson et al. 2006). IL-2 has been previously 
identifi ed as a key cytokine for Treg development. Nunes-Cabaco et al. 
have also shown that IL-7 signalling induces STAT5 activation in DP 
FOXP3+ thymocytes (Nunes-Cabaco, Caramalho et al. 2011). A recent 
study of human Treg development reported that IL-2 and IL-15 equally 
promoted Treg diff erentiation, focusing on the CD4SP stage (Caramalho, 
Nunes-Silva et al. 2015). In our study all three cytokines IL-2, IL-7 and 
IL-15 induced FOXP3 expression, promoted the regulatory phenotype and 
enhanced survival of FOXP3 thymocytes in the DP phase. The main impact 
was detected at the DP CD3high stage after positive selection.
Peripheral mature human regulatory T cells are characterized as CD127 (IL-
7Rα) negative and are not responsive to IL-7. However, in the human thymus 
developing DP FOXP3+ cells have relatively high expression of CD127 
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and stimulation with IL-7 upregulates STAT5 phosphorylation levels of DP 
FOXP3+ population. We also show that DP Tregs downregulate CD127 
expression in response to IL-7. This indicates that DP FOXP3+ cells are 
responsive to IL-7 since it is able to directly modulate their receptor levels. 
SOCS1, a negative regulator in DP thymocytes, does not seem to have an 
eff ect on IL-7 signalling in DP FOXP3+ cells. A recent human in-vitro 
study considered IL-7 to play only a minor role in human Treg development 
(Caramalho, Nunes-Silva et al. 2015). In our study we show that human 
DP thymocytes are responsive to IL-7 and IL-7 increases the frequency 
of FOXP3+ cells and promotes Treg phenotype. Although CD127 was 
downregulated in the transition from DP to CD4SP stage, CD4SP FOXP3+ 
thymocytes remained responsive to IL-7. Exposure to IL-7 also increased 
their frequency and expression of Treg-associated markers. 
To further investigate Treg development we studied the mechanisms of 
the diff erent cytokines. At the CD4+CD8+ stage FOXP3+ thymocytes are 
highly susceptible to apoptosis but all three common γ chain cytokines 
selectively rescued them from cell death. They also upregulated the 
expression of anti-apoptotic BCL-2 in the DP population. In contrast to 
IL-2 and IL-7, IL-15 did not aff ect BCL-2 expression in the positively 
selected DP CD3high population but at the earlier CD3low stage. It has been 
previously reported that cytokines also increase proliferation of FOXP3+ 
cells (Caramalho, Nunes-Silva et al. 2015) but we did not detect an increase 
of Ki-67 expression in the Treg population. However, this might be due to 
shorter culture time. We used only overnight cultures and thus the eff ect 
of common γ chain cytokines on the proliferation rate cannot be ruled out. 
Our results support a two-step model that has been well established in 
murine models. However, in the human thymus developing Tregs are 
clearly detected already at the DP stage. In the positive selection TCR 
signalling dictates Treg maturation and IL-15 enhances their survival. 
At the DP CD3high stage IL-2 and IL-7 increase the expression of BCL-
2, suppress apoptosis and promote Treg phenotype before FOXP3+ cells 
migrate to the medulla.
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Figure 8. TCR diversity and the development of FOXP3 regulatory T 
cells in the human thymus. Thymic TCR diversity is generated by somatic 
recombination of the TCR β chain locus at the DN stage and of the α chain 
locus at the DP stage. The diverse repertoire includes also the thymocytes 
instructed to develop into regulatory T cell lineage. Commitment to Treg 
lineage can occur at the DP or CD4SP stage during thymic development. 
The role of TCR-signals is essential for Treg development during positive 
selection. At the DP CD3high stage IL-2 and IL-7 upregulate the expression 




In this thesis I have studied T cell receptor diversity, the repertoire of 
developing regulatory T cells and the factors dictating regulatory T cell 
development in the human thymus. Analysis of TCR repertoire in the 
entire thymus provides knowledge of recombination machinery and thymic 
selections. Human intrathymic TCR repertoire diversity has not been 
previously studied and here we have estimated for the fi rst time the total 
thymic diversity. Our estimation data showed an extremely diverse but 
transient TCR repertoire consisting of 40-70 x 106 unique TCRβ sequences 
and 60-100 x 106 TCRα sequences. Our directly measured diversity of 
10.3 x 106 unique TCRβ sequences and 3.7 x 106 TCRα sequences sets 
a new lower limit for TCR repertoire diversity. Previous estimates have 
been based on sequencing peripheral repertoire in human blood samples. 
In contrast to the data from peripheral repertoire, we report TCRα diversity 
to be 2-fold higher than TCRβ diversity in the thymus. In the future TCR 
sequencing and single-cell technologies will provide methods for the 
deeper characterisation of diff erent developmental stages and selections in 
the thymus. Studying TCR repertoires in autoimmune diseases and cancer 
can provide new insights into disease mechanisms and thus even new 
therapy options.
The diverse thymic repertoire also includes thymocytes that are instructed 
to diff erentiate into regulatory T cell lineage. The developmental pathway 
of natural regulatory T cells has been extensively studied in murine 
models but there are notable diff erences between human and murine Treg 
development. In the human thymus the commitment to Treg lineage can 
occur already at the CD4+CD8+ double positive stage and thus this thesis 
focuses on regulatory T cell diff erentiation and dictating cytokines at the 
DP stage. Tregs are characterised by the demethylation of Treg-specifi c-
demethylated region and stable expression of the forkhead/winged-helix 
transcription factor FOXP3. To track the timing of Treg commitment we 
have used high-throughput TCR sequencing and methylation analysis 
of the TSDR. Comparing the common unique and total number of TCR 
nucleotide sequences showed that regulatory DP CD25+ and CD4SP CD25+ 
populations were clearly closer to each other than any other population, 
indicating that they are part of the common clone and developmental 
pathway. Comparing the methylation status of DP and CD4SP regulatory 
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populations showed no diff erence between them; a stable Treg phenotype 
can already be detected at the DP stage. This supports the previously 
reported human data which shows that the commitment to the regulatory 
lineage occurs at the CD4+CD8+ DP stage. 
The common γ chain cytokines IL-2, IL-7 and IL-15 play an essential 
role in human regulatory T cell development. The signifi cance of IL-2 
for Treg diff erentiation has been well reported in murine models but IL-7 
has been considered less important since mature peripheral Tregs express 
low levels of CD127. However, we show that during thymic development 
DP FOXP3+ thymocytes express CD127 and are responsive to IL-7. 
TCR signalling modulates Treg maturation at the DP stage but after 
positive selection cytokines upregulate FOXP3 expression, promote Treg 
phenotype and enhance the survival of DP FOXP3+ thymocytes. They are 
highly susceptible to apoptosis but IL-2, IL-7 and IL-15 avert cell death and 
upregulate the expression of anti-apoptotic protein BCL-2. Suppressing 
apoptosis seems to be a key mechanism for promoting Treg development 
at both the DP and CD4SP stage. Studying involvement of common γ chain 
cytokines in Treg development gives new insight into the timing of Treg 
commitment and selections of TCR repertoires.
Regulatory T cells maintain peripheral immunological tolerance and 
prevent harmful autoimmunity reactions. Research of normal Treg 
development provides the basis for recognising the mechanisms that lead 
to loss of tolerance. In the future manipulating Treg responses in humans 
could provide new applications for therapeutic interventions. 
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